



Prior Authorization Requirements

Effective: 12/01/2017

CommuniCare Advantage Cal MediConnect Plan (Medicare-Medicaid Plan) is a health plan that contracts with both Medicare and Medi-Cal to provide benefits of both programs to enrollees.

This is not a complete list of drugs covered by our plan. For a complete and current listing, please call Member Services 24 hours a day, seven days a week at 1-888-244-4430 or TTY 1-855-266-4584 or visit www.chgsd.com. This is not a complete list of all formulary alternatives covered by the Part D sponsor for the drug you have selected.

ABALOPARATIDE

Products Affected

- Tymlos

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	ONE OF THE FOLLOWING: (1) HIGH RISK FOR FRACTURES DEFINED AS ONE OF THE FOLLOWING: HISTORY OF OSTEOPOROTIC (I.E., FRAGILITY, LOW TRAUMA) FRACTURE(S). 2 OR MORE RISK FACTORS FOR FRACTURE (E.G., HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS SUCH AS NAFARELIN, ETC.). NO PRIOR TREATMENT FOR OSTEOPOROSIS AND FRAX SCORE OF AT LEAST 20% FOR ANY MAJOR FRACTURE OR OF AT LEAST 3% FOR HIP FRACTURE. (2) UNABLE TO USE ORAL THERAPY (I.E., UPPER GASTROINTESTINAL PROBLEMS UNABLE TO TOLERATE ORAL MEDICATION, LOWER GASTROINTESTINAL PROBLEMS UNABLE TO ABSORB ORAL MEDICATIONS, TROUBLE REMEMBERING TO TAKE ORAL MEDICATIONS OR COORDINATING AN ORAL BISPHOSPHONATE WITH OTHER ORAL MEDICATIONS OR THEIR DAILY ROUTINE). (3) ADEQUATE TRIAL OF, INTOLERANCE TO, OR A CONTRAINDICATION TO BISPHOSPHONATES (E.G., ALENDRONATE, RISEDRONATE, IBANDRONATE).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 MONTHS
Other Criteria	N/A

ABATACEPT IV

Products Affected

- Orenzia (with maltose)

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, JUVENILE IDIOPATHIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. JIA: 4 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. JUVENILE IDIOPATHIC ARTHRITIS (JIA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

ABATACEPT SQ

Products Affected

- Orenzia
- Orenzia ClickJect

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

ABEMACICLIB

Products Affected

- Verzenio

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ABIRATERONE

Products Affected

- Zytiga

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ACETAMINOPHEN OTC

Products Affected

- ACETAMINOPHEN 160 MG/5 ML ELX
- CHILD ACETAMINOPHEN 80 MG/2.5 ML ORAL SYRINGE 50'S, U-D, ORAL SYR
- CHILD NON-ASPIRIN 160 MG/5 ML CHILDREN'S
- CHILD PAIN-FEVER 160 MG/5 ML
- CHILD PAIN-FEVER 160 MG/5 ML A/F, ASA/F, IBU/F
- CVS CHILD PAIN RLF 160 MG/5 ML CHILDREN'S, A/F
- INFANT PAIN RELV 80 MG/0.8 ML A/F, GLUTEN-FREE
- INFANT'S PAIN RELIEF SUSP DROP
- LITTLE REMEDIES FEVER 160 MG/5 A/F,D/F, GLUTEN-FREE
- MAPAP 160 MG/5 ML LIQUID
- MAPAP 160 MG/5 ML SUSPENSION
- NON-ASPIRIN CHILD'S DROPS
- NORTEMP 80 MG/0.8 ML DROP
- PEDIACARE FEVER REDUCER SUSP
- PV CHILDREN'S NON-ASA LIQ
- PV INFANT NON-ASA 80 MG/0.8 ML ASPIRIN FREE, A/F
- RA INFANT FEVER-PAIN REL SUSP
- RA NON-ASPIRIN 160 MG/5 ML CHILDREN'S, CHERRY
- SILAPAP INFANT'S DROPS
- INFANT'S

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO INDIVIDUALS YOUNGER THAN 21 YEARS OF AGE FOR THE LIQUID AND DROPS ONLY.

ADALIMUMAB

Products Affected

- Humira
- Humira Pediatric Crohn's Start
- Humira Pen
- Humira Pen Crohn's-UC-HS Start
- Humira Pen Psoriasis-Uveitis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: CURRENT WEIGHT. PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: RA: 6 MO. PSA/AS: 4 MO. PJIA: 5 MO. PSO/CD/UC/HS: 3 MO. UVEITIS: 6 MO. RENEW: 12 MO FOR ALL

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS: TRIAL OF FORMULARY AGENTS NOT REQUIRED. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF ONE OF THE FOLLOWING CONVENTIONAL THERAPIES SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE.</p>

AFATINIB DIMALEATE

Products Affected

- Gilotrif

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ALECTINIB

Products Affected

- Alecensa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ALEMTUZUMAB - LEMTRADA

Products Affected

- Lemtrada

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 1 MONTH. RENEWAL: 12 MONTHS.
Other Criteria	TRIAL WITH TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR GLATIRAMER. RENEWAL REQUESTS FOR ALEMTUZUMAB REQUIRE THAT AT LEAST 12 MONTHS HAVE ELAPSED SINCE RECEIVING THE FIRST COURSE OF LEMTRADA. PATIENTS ARE LIMITED TO TWO COURSES OF THERAPY WITH LEMTRADA WITHIN A LIFETIME.

ALIROCUMAB

Products Affected

- Praluent Pen
- Praluent Syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>MUST HAVE A LDL CHOLESTEROL LEVEL GREATER THAN 100MG/DL WHILE ON MAXIMAL DRUG TREATMENT FOR THE PAST 2 MONTHS AND ONE OF THE FOLLOWING DIAGNOSES: (1) HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) DETERMINED BY SIMON BROOME DIAGNOSTIC CRITERIA FOR HEFH OR A SCORE OF 6 OR GREATER ON THE DUTCH LIPID NETWORK CRITERIA FOR HEFH OR (2) HISTORY OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AS DOCUMENTED BY PHYSICIAN ATTESTATION. PATIENT MUST NOT HAVE CONCURRENT USE OF REPATHA OR OTHER PCSK9 AGENT. INITIAL THERAPY: FOR STATIN TOLERANT PATIENTS: MUST HAVE TAKEN ATORVASTATIN OR ROSUVASTATIN FOR THE PAST 2 MONTHS. FOR STATIN INTOLERANT PATIENTS: DOCUMENTATION OF STATIN INTOLERANCE BY ONE OF THE FOLLOWING: (1) PHYSICIAN ATTESTATION, (2) PATIENT HAS TRIED ROSUVASTATIN, ATORVASTATIN, OR STATIN THERAPY AT ANY DOSE AND HAS EXPERIENCED SKELETAL-MUSCLE RELATED SYMPTOMS (E.G., MYOPATHY). PATIENTS WITH CONTRAINDICATIONS TO STATINS INCLUDING ACTIVE DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT OR HYPERSENSITIVITY REACTIONS WILL BE APPROVED FOR PRALUENT THERAPY WITHOUT REQUIREMENT OF DOCUMENTATION OF STATIN INTOLERANCE. RENEWAL CRITERIA: RECEIVING PRIOR PRALUENT THERAPY FOR THE PAST 6 MONTHS AND NO CLAIMS FOR REPATHA, JUXTAPID, OR KYNAMRO SINCE PRALUENT APPROVAL.</p>

AMANTADINE

Products Affected

- Gocovri oral capsule, extended release 24hr
137 mg, 68.5 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ANAKINRA

Products Affected

- Kineret

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. NOMID/CAPS: 12 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA.

ANTI-HISTAMINES AND DECONGESTANTS

Products Affected

- 12 HOUR RELIEF TABLET
- 25DPH-7.5PEH LIQUID
- ALA-HIST IR 2 MG TABLET
- ALA-HIST PE TABLET
- ALAVERT 10 MG ODT
- ALLER-CHLOR 2 MG/5 ML SYRUP
- ALLER-CHLOR 4 MG TABLET
- ALLERGY 4 MG TABLET
- ALLERHIST-1 1.34 MG TABLET
- AMBI 60PSE-4CPM TABLET
- APRODINE TABLET
- BROTAPP LIQUID
- CETIRIZINE HCL 1 MG/ML SOLN CHILDREN, S/F, GRAPE (OTC)
- CETIRIZINE HCL 10 MG CHEW TAB CHILDREN'S, OUTER, U-D
- CETIRIZINE HCL 10 MG TABLET
- CETIRIZINE HCL 5 MG CHEW TAB CHILDREN'S, OUTER, U-D
- CETIRIZINE HCL 5 MG TABLET
- CHILD ALLEGRA ALLERGY 30 MG/5 ML SUSPENSION
- CHILD DOMETUSS-DA LIQUID
- CHILD LORATADINE 5 MG/5 ML SYR GRAPE, S/F
- CHILD TRIAMINIC COLD & ALLERGY
- CHILD WAL-TAP COLD-ALLERGY ELX
- CHILD WAL-ZYR 1 MG/ML SOLUTION CHERRY
- CHILD'S ALLER-TEC 1 MG/ML SOLN
- CHILD'S WAL-ZYR 10 MG CHEW TAB
- CHILDREN'S COLD & ALLERGY ELXR A/F
- CHILDREN'S SILFEDRINE LIQ
- CHILDREN'S WAL-FEX 30 MG/5 ML
- CHILDS SUDAFED 15 MG/5 ML LIQ NON-DROWSY, A/F, S/F
- CHLORHIST 4 MG TABLET
- CHLORPHENIRAMINE ER 12 MG TAB
- Cold-Allergy-Sinus
- CONEX SOLUTION
- CONEX TABLET
- CVS ALLERGY-D TABLET
- CVS CHILD ALLERGY 10 MG CHW TB 24 HR, INDOOR/OUTDOOR
- CVS COLD & COUGH NIGHTTIME LIQ
- CVS MOTION SICKNESS RELIEF TAB CHEWABLE TABLET
- CVS NOSE DROPS
- DAILYHIST-1 1.34 MG TABLET
- DALLERGY 1-5 MG TABLET
- DAYHIST ALLERGY 1.34 MG TABLET 12 HR RELIEF
- DAYHIST TABLET
- DIMAPHEN ELIXIR A/F, GRAPE, GLUTEN-F
- DIMETAPP COLD & CONGEST LIQUID
- DRAMAMINE LESS DROWSY 25 MG TB
- ED CHLORPED DROPS
- ED CHLORPED JR SYRUP
- ED-A-HIST 4 MG-10 MG TABLET
- ENTRE-HIST PSE LIQUID
- EQ ALLERGY & SINUS RELIEF TAB
- EQL ALLERGY RELIEF 10 MG ODT NON-DROWSY
- EQL NASAL DECNGSTNT NOSE DROPS
- FEXOFENADINE HCL 180 MG TABLET 24 HOUR, NON-DROWSY (OTC)
- FEXOFENADINE HCL 30 MG/5 ML
- FEXOFENADINE HCL 60 MG TABLET INDOOR/OUTDOOR (OTC)
- HIST-PSE SOLUTION
- HISTEX-PE SYRUP

- KRO CHILD NITE TIME COLD & CGH
- LOHIST-D LIQUID
- LORATADINE 10 MG TABLET
- MECLIZINE 12.5 MG CAPLET CAPLET (OTC)
- MECLIZINE 25 MG TABLET (OTC)
- MEDI-MECLIZINE 25 MG TABLET OUTER, F/C
- MEDI-PHEDRINE 30 MG TABLET
- NASAL DECONGEST-ANTIHIST TAB
- NASAL-SINUS DECONGEST TAB
- NOHIST-LQ LIQUID
- NOSE DROPS
- PEDIAVENT 1 MG TABLET CHEW
- PEDIAVENT 2 MG/5 ML SYRUP
- PHENYLEPHRINE-PYRILAMINE 10-25
- PHENYLHISTINE DH LIQUID (OTC)
- PROMETHAZINE VC-CODEINE SYRUP
- PROMETHAZINE-CODEINE SYRUP
- PROMETHAZINE-DM SYRUP
- PSEUDOEPHED 30 MG/5 ML SOLN
- PSEUDOEPHEDRINE 30 MG TABLET
- PSEUDOEPHEDRINE 60 MG TABLET EX-STR, NON DROWSY (OTC)
- PV SINUS NIGHTTIME TABLET
- PYRILAMINE-PHENYLEPHRINE SUSP
- RA ACTA-TABS PE TABLET
- RA ALLERGY PLUS SINUS TABLET
- RA CHILD CETIRIZINE 10 MG CHEW 24 HR, INDOOR/OUTDOOR
- RA LORATADINE 10 MG TABLET NON-DROWSY
- RA MOTION SICKNESS RLF TB CHEW RASPBERRY FLAVOR
- RITIFED SYRUP
- RYMED TABLET
- SM ADULT NASAL DECONGESTANT LQ
- SM ALLERGY RELIEF 1.34 MG TAB
- SM COLD & ALLERGY TABLET
- SM SINUS AND ALLERGY TABLET
- MAXIMUM STRENGTH
- SUDOGEST 30 MG TABLET BOXED
- SUDOGEST 60 MG TABLET
- SUDOGEST SINUS & ALLERGY TAB
- SUPHEDRIN LIQUID
- TRAVEL SICKNESS 25 MG TAB CHEW
- TRAVEL-EASE 25 MG TABLET
- TRIP-PSE LIQUID
- V-R TRIACTING ORANGE SYRUP
- VALU-TAPP DECONGESTANT DROP
- VAZOBID-PD SUSPENSION
- VAZOTAB 10-25 MG TABLET
- WAL-ACT D COLD & ALLERGY TAB
- WAL-DRYL-D ALLERGY & SINUS CPT
- WAL-FEX ALLERGY 180 MG TABLET
- WAL-FEX ALLERGY 60 MG TABLET
- WAL-FINATE 4 MG TABLET
- WAL-FINATE-D TABLET
- WAL-ITIN 10 MG ODT NON-DROWSY
- WAL-ITIN 10 MG TABLET NON-DROWSY, 24 HR RLF
- WAL-ITIN 5 MG/5 ML SYRUP CHILDREN'S, GRAPE
- WAL-PHED 30 MG TABLET NON-DROWSY
- WAL-PHED PE SINUS-ALLERGY TAB
- WAL-PHED SINUS AND ALLERGY TAB
- WAL-TAP ELIXIR
- WAL-ZYR 10 MG TABLET
- ZEPHREX-D 30 MG TABLET

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO INDIVIDUALS 2 YEARS OF AGE AND OLDER.

ANTI-HISTAMINES AND DECONGESTANTS - DIPHENHYDRAMINE

Products Affected

- ALER-CAPS 25 MG CAPSULE
- ALER-TAB 25 MG TABLET
- ALKA-SELTZER PLUS ALLERGY TAB
- ANTIHISTAMINE 25 MG CAPSULE
- BANOPHEN 25 MG CAPSULE
- BANOPHEN 25 MG TABLET
- BANOPHEN 50 MG CAPSULE
- BANOPHEN ALLERGY 12.5 MG/5 ML A/F
- BENADRYL ALLERGY 25 MG ULTRATB ULTRATAB
- CHILD'S BENADRYL 12.5 MG/5 ML
- COMPOZ 25 MG GELCAP
- DIPHEDRYL 12.5 MG/5 ML ELIXIR
- DIPHENHIST 12.5 MG/5 ML SOLN
- DIPHENHIST 25 MG CAPSULE
- DIPHENHIST 25 MG CAPTAB CAPTAB
- DIPHENHYDRAMINE 25 MG CAPSULE (OTC)
- EQ ALLERGY RELIEF 25 MG TABLET
- GERI-DRYL 12.5 MG/5 ML LIQUID
- HM Z-SLEEP 25 MG SOFTGEL
- NYTOL 25 MG QUICKCAPS CAPLET CAPLET
- PV NYT-TIME SLEEP 25 MG CAPLET
- RA ALLERGY MED 25 MG CAPSULE
- RA ALLERGY MED 25 MG TABLET
- RA ALLERGY MED 25 MG TABLET COATED MINITABS
- RA SLEEP TABLET
- RA SLEEP-AID SOFTGEL
- SILADRYL 12.5 MG/5 ML LIQUID
- SIMPLY SLEEP 25 MG CAPLET CAPLET
- UNISOM 50 MG SLEEPGELS SOFTGEL
- VALU-DRYL ALLERGY MED TAB
- VICKS QLEARQUIL NIGHT 25 MG
- WAL-DRYL ALLERGY 12.5 MG/5 ML CHILDREN,A/F,S/F,D/F
- WAL-DRYL ALLERGY 25 MG CAPSULE
- WAL-DRYL ALLERGY 25 MG MINITAB MINITAB, COATED
- WAL-SLEEP Z 25 MG ODT
- WAL-SLEEP Z 25 MG SOFTGEL
- WAL-SOM 25 MG ODT
- WAL-SOM 50 MG SOFTGEL SOFTGEL

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A

PA Criteria	Criteria Details
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO USE IN THE TREATMENT OF ALLERGIES OR ALLERGIC CONDITIONS ONLY AND TO INDIVIDUALS 2 YEARS OF AGE AND OLDER.

ANTI-OBESITY AGENTS -PHENTERMINE

Products Affected

- LOMAIRA 8 MG TABLET
- PHENTERMINE 15 MG CAPSULE
- PHENTERMINE 30 MG CAPSULE
- PHENTERMINE 37.5 MG CAPSULE
- PHENTERMINE 37.5 MG TABLET

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	REQUEST FOR PHENTERMINE FOR THE MANAGEMENT OF WEIGHT LOSS OR WEIGHT MANAGEMENT IS RESTRICTED TO INDIVIDUALS 17 YEARS OF AGE OR OLDER. COVERED USES ONLY FOR FDA APPROVED INDICATIONS. CRITERIA TO BE MET INCLUDE ONE OF THE FOLLOWING: A BODY MASS INDEX (BMI) OF 30 KG/M2 OR GREATER OR A BMI OF 27 KG/M2 OR GREATER AND AT LEAST ONE WEIGHT-RELATED CO-MORBIDITY SUCH AS HYPERTENSION, TYPE 2 DIABETES MELLITUS, OR HYPERLIPIDEMIA.

APREMILAST

Products Affected

- Otezla
- Otezla Starter

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST
Coverage Duration	INITIAL: PSORIATIC ARTHRITIS: 4 MONTHS. PSORIASIS: 5 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL WITH HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA AND ONE CONVENTIONAL THERAPY SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE.

ASFOTASE

Products Affected

- Strensiq

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION, SERUM ALKALINE PHOSPHATASE (ALP) LEVEL, SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS, URINE PHOSPHOETHANOLAMINE (PEA) LEVEL, RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP)
Age Restrictions	PERINATAL/INFANTILE-ONSET HYPOPHOSPHATASIA (HPP): 6 MONTHS OF AGE OR YOUNGER AT HYPOPHOSPHATASIA (HPP) ONSET. JUVENILE-ONSET HYPOPHOSPHATASIA (HPP) 18 YEARS OF AGE OR YOUNGER AT HYPOPHOSPHATASIA (HPP) ONSET.
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH AN ENDOCRINOLOGIST, A GENETICIST, OR A METABOLIC SPECIALIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: FOR PATIENTS WITH PERINATAL/INFANTILE-ONSET HYPOPHOSPHATASIA (HPP), ALL OF THE FOLLOWING CRITERIA MUST BE MET: POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR MEETS AT LEAST TWO OF THE FOLLOWING CRITERIA: 1.) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE 2.) SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS ELEVATED AND PATIENT HAS NOT RECEIVED VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK 3.) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE 4.) RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP) (E.G., FLARED AND FRAYED METAPHYSES, OSTEOPENIA, WIDENED GROWTH PLATES, AREAS OF RADIOLUCENCY OR SCLEROSIS) 5.) PRESENCE OF TWO OR MORE OF THE FOLLOWING: RACHITIC CHEST DEFORMITY, CRANIOSYNOSTOSIS (PREMATURE CLOSURE OF SKULL BONES), DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, NEPHROCALCINOSIS, OR HISTORY OF ELEVATED SERUM CALCIUM HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. FOR PATIENTS WITH JUVENILE-ONSET HYPOPHOSPHATASIA (HPP), ALL OF THE FOLLOWING CRITERIA MUST BE MET: POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR MEETS AT LEAST TWO OF THE FOLLOWING CRITERIA:1.) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE 2.) SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS ELEVATED AND PATIENT HAS NOT RECEIVED VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK 3.)URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE 4.)RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP) (E.G., FLARED AND FRAYED METAPHYSES, OSTEOPENIA, OSTEOMALACIA, WIDENED GROWTH PLATES, AREAS OF RADIOLUCENCY OR SCLEROSIS) 5.)PRESENCE OF TWO OR MORE OF THE FOLLOWING:RACHITIC DEFORMITIES (RACHITIC CHEST,</p>

PA Criteria	Criteria Details
	<p>BOWED LEGS, KNOCK-KNEES),PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, OR HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. STRENSIQ WILL NOT BE APPROVED FOR THE FOLLOWING PATIENTS: PATIENTS CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE (E.G., BONIVA (IBANDRONATE), FOSAMAX (ALENDRONATE), ACTONEL (RISEDRONATE)), PATIENTS WITH SERUM CALCIUM OR PHOSPHATE LEVELS BELOW THE NORMAL RANGE, PATIENTS WITH A TREATABLE FORM OF RICKETS. RENEWAL: PATIENT HAS EXPERIENCED AN IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HYPOPHOSPHATASIA (HPP) (E.G., IMPROVEMENT OF THE IRREGULARITY OF THE PROVISIONAL ZONE OF CALCIFICATION, PHYSEAL WIDENING, METAPHYSEAL FLARING, RADIOLUCENCIES, PATCHY OSTEOSCLEROSIS, RATIO OF MID-DIAPHYSEAL CORTEX TO BONE THICKNESS, GRACILE BONES, BONE FORMATION AND FRACTURES.</p>

ASPARAGINASE

Products Affected

- Oncaspar

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 MONTHS
Other Criteria	

ATEZOLIZUMAB

Products Affected

- Tecentriq

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

AVELUMAB

Products Affected

- Bavencio

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

AXITINIB

Products Affected

- Inlyta oral tablet 1 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF AT LEAST ONE SYSTEMIC THERAPY FOR THE TREATMENT OF RCC SUCH AS NEXAVAR (SORAFENIB), TORISEL (TEMSIROLIMUS), SUTENT (SUNITINIB), VOTRIENT (PAZOPANIB), OR AVASTIN (BEVACIZUMAB) IN COMBINATION WITH INTERFERON.

BEDAQUILINE FUMARATE

Products Affected

- Sirturo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	
Coverage Duration	24 WEEKS
Other Criteria	SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS.

BELIMUMAB

Products Affected

- Benlysta intravenous
- Benlysta subcutaneous

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	AUTOANTIBODY POSITIVE LUPUS TEST.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEMBER IS CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. NO APPROVAL FOR DIAGNOSIS OF SEVERE ACTIVE LUPUS NEPHRITIS, SEVERE CENTRAL NERVOUS SYSTEM LUPUS OR CONCURRENT USE OF BIOLOGIC AGENTS OR INTRAVENOUS CYCLOPHOSPHAMIDE. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.

BELINOSTAT

Products Affected

- Beleodaq

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BENDAMUSTINE

Products Affected

- Bendeka

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BEVACIZUMAB

Products Affected

- Avastin

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BEXAROTENE

Products Affected

- bexarotene
- Targretin oral
- Targretin topical

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BLINATUMOMAB

Products Affected

- Blincyto intravenous kit

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: DIAGNOSIS OF PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A PATIENT WHO HAS PREVIOUSLY TRIED CHEMOTHERAPY BUT HAS RELAPSED OR IS REFRACTORY TO TREATMENT. INITIAL APPROVAL IS FOR 2 CYCLES, MAY APPROVE FOR 1 ADDITIONAL CYCLE DUE TO TREATMENT INTERRUPTION FOR DOSE MODIFICATION. RENEWAL IS APPROVED FOR PATIENTS WHO HAVE ACHIEVED COMPLETE REMISSION WITH OR WITHOUT PARTIAL HEMATOLOGICAL RECOVERY OF PERIPHERAL BLOOD COUNTS AFTER 2 CYCLES OF TREATMENT. RENEWAL IS NOT APPROVED FOR PATIENTS WHO RECEIVED AN ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT.

BORTEZOMIB

Products Affected

- Velcade

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BOSUTINIB

Products Affected

- Bosulif oral tablet 100 mg, 500 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CML: BCR-ABL MUTATIONAL ANALYSIS CONFIRMING THAT BOTH T315I AND V299L MUTATIONS ARE NOT PRESENT.

BRENTUXIMAB

Products Affected

- Adcetris

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

BRIGATINIB

Products Affected

- Alunbrig

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 MONTHS
Other Criteria	N/A

BRODALUMAB

Products Affected

- Siliq

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. PATIENT HAS BEEN COUNSELED ON AND EXPRESSES UNDERSTANDING OF THE RISK OF SUICIDAL IDEATION AND BEHAVIOR. RENEWAL: PATIENT HAS NOT DEVELOPED OR REPORTED WORSENING DEPRESSIVE SYMPTOMS OR SUICIDAL IDEATION AND BEHAVIORS WHILE ON TREATMENT WITH SILIQ.

C1 ESTERASE INHIBITOR

Products Affected

- Cinryze
- Haegarda

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HEMATOLOGIST, IMMUNOLOGIST
Coverage Duration	12 MONTHS
Other Criteria	

CABOZANTINIB

Products Affected

- Cometriq

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

CABOZANTINIB S-MALATE - CABOMETYX

Products Affected

- Cabometyx oral tablet 20 mg, 40 mg, 60 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PATIENT HAS RECEIVED PRIOR ANTIANGIOGENIC THERAPY (E.G., SUTENT [SUNITINIB], VOTRIENT [PAZOPANIB], INLYTA [AXITINIB], NEXAVAR [SORAFENIB])

CANAKINUMAB

Products Affected

- Ilaris (PF)

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	CAPS: 4 YEARS AND OLDER. SJIA: 2 YEARS AND OLDER.
Prescriber Restrictions	PRESCRIBED OR SUPERVISED BY RHEUMATOLOGIST, DERMATOLOGIST, OR AN IMMUNOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	

CANNABINOIDS

Products Affected

- dronabinol

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	B VS D COVERAGE CONSIDERATION. PART D COVERAGE CONSIDERATION FOR A DIAGNOSIS OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY REQUIRES A TRIAL OF OR CONTRAINDICATION TO CONVENTIONAL ANTIEMETIC THERAPIES SUCH AS ONDANSETRON, STEROIDS INDICATED FOR EMESIS OR EMEND. NO ADDITIONAL REQUIREMENTS FOR A DIAGNOSIS OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS.

CARFILZOMIB

Products Affected

- Kyprolis intravenous recon soln 30 mg, 60 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

CERITINIB

Products Affected

- Zykadia

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	POSITIVE FOR ANAPLASTIC LYMPHOMA KINASE (ALK) FUSION ONCOGENE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

CERTOLIZUMAB PEGOL

Products Affected

- Cimzia
- Cimzia Powder for Reconst

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS/ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. CROHN'S DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. PSA/AS: 4 MONTHS. CD: 12 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS: PREVIOUS TRIAL OF HUMIRA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA AND ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE.

CLOBAZAM

Products Affected

- Onfi oral suspension
- Onfi oral tablet 10 mg, 20 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	2 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF LAMOTRIGINE OR TOPIRAMATE. REQUESTS FOR ORAL SUSPENSION APPROVABLE IF PATIENT IS UNABLE TO SWALLOW OR IS UNDER THE AGE OF 5 YEARS.

COBIMETINIB FUMARATE

Products Affected

- Cotellic

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

COPANLISIB DI-HCL

Products Affected

- Aliqopa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

CRIZOTINIB

Products Affected

- Xalkori

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER IS ANAPLASTIC LYMPHOMA KINASE POSITIVE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DABRAFENIB MESYLATE

Products Affected

- Tafinlar

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DACLATASVIR

Products Affected

- Daklinza

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI, SOVALDI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. NO APPROVALS FOR CONCURRENT USE WITH ANY OF THESE (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER) MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, OR RIFAMPIN. APPROVAL FOR INTERFERON INELIGIBLE PATIENTS - INTERFERON INELIGIBILITY INCLUDES CONCURRENT DIAGNOSIS OF AUTOIMMUNE HEPATITIS OR OTHER AUTOIMMUNE DISORDER, A KNOWN HYPERSENSITIVITY REACTION (SUCH AS URTICARIA, ANGIOEDEMA, BRONCHOCONSTRICTION AND ANAPHYLAXIS TO ALPHA INTERFERONS, PEG, OR ANY COMPONENT OF PEGINTERFERON), DOCUMENTED DEPRESSION, DECOMPENSATED HEPATIC DISEASE: A BASELINE NEUTROPHIL COUNT BELOW 1,500 PER MICROLITER, A BASELINE PLATELET COUNT BELOW 90,000, OR A BASELINE HEMOGLOBIN BELOW 10G/DL THAT HAS NOT RESPONDED TO TREATMENT.</p>

DACLIZUMAB

Products Affected

- Zinbryta

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	PRE-EXISTING HEPATIC DISEASE OR IMPAIRMENT, INCLUDING: ACTIVE HEPATITIS B AND C, AUTOIMMUNE HEPATITIS OR OTHER AUTOIMMUNE CONDITIONS INVOLVING THE LIVER, BASELINE ALT AND AST GREATER THAN OR EQUAL TO 2 TIMES UPPER LIMIT OF NORMAL (ULN).
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	PREVIOUS TRIAL OF TWO OF THE FOLLOWING PREFERRED AGENTS FOR MULTIPLE SCLEROSIS, SUCH AS AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR FORMULARY GLATIRAMER ACETATE. RENEWAL: REQUESTS FOR DACLIZUMAB WILL NOT BE APPROVED FOR THE FOLLOWING PATIENTS: PATIENT WITH AUTOIMMUNE HEPATITIS OR HEPATIC INJURY.

DALFAMPRIDINE

Products Affected

- Ampyra

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA.
Age Restrictions	
Prescriber Restrictions	NEUROLOGIST
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT IN WALKING ABILITY.

DARATUMUMAB

Products Affected

- Darzalex

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DASATINIB

Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREVIOUSLY-TREATED CHRONIC MYELOID LEUKEMIA (CML) REQUIRES BCR-ABL MUTATIONAL ANALYSIS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, V299L, T315A, F317L/V/I/C.

DEFLAZACORT

Products Affected

- Emflaza oral suspension mg
- Emflaza oral tablet 18 mg, 30 mg, 36 mg, 6

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST SPECIALIZING IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD).
Coverage Duration	12 MONTHS
Other Criteria	

DESIRUDIN

Products Affected

- Iprivask

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 MONTH
Other Criteria	

DEUTETRABENAZINE

Products Affected

- Austedo oral tablet 12 mg, 6 mg, 9 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DICHLORPHENAMIDE

Products Affected

- Keveyis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	HEPATIC INSUFFICIENCY, PULMONARY OBSTRUCTION, OR A HEALTH CONDITION THAT WARRANTS CONCURRENT USE OF HIGH-DOSE ASPIRIN
Required Medical Information	
Age Restrictions	18 YEARS AND OLDER
Prescriber Restrictions	
Coverage Duration	INITIAL: 2 MONTHS RENEWAL: 12 MONTHS
Other Criteria	RENEWAL REQUIRES THE PATIENT EXPERIENCED AT LEAST TWO FEWER ATTACKS PER WEEK FROM THEIR BASELINE

DICLOFENAC EPOLAMINE

Products Affected

- Flector

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DIMETHYL FUMARATE

Products Affected

- Tecfidera oral capsule, delayed release(DR/EC) 120 mg, 120 mg (14)- 240 mg (46), 240 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DINUTUXIMAB

Products Affected

- Unituxin

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

DROXIDOPA

Products Affected

- Northera

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE (LYING FACE UP) POSITION AT BASELINE AND RENEWAL.
Age Restrictions	18 YEARS OF AGE AND OLDER
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST
Coverage Duration	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
Other Criteria	INITIAL: DIAGNOSIS OF ORTHOSTATIC HYPOTENSION AS DOCUMENTED BY A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION. RENEWAL: PATIENT HAD AN INCREASE IN SYSTOLIC BLOOD PRESSURE FROM BASELINE OF AT LEAST 10 MMHG UPON STANDING FROM A SUPINE (LAYING FACE UP) POSITION.

DUPILUMAB

Products Affected

- Dupixent

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PATIENT HAS MINIMUM BODY SURFACE AREA (BSA) INVOLVEMENT OF AT LEAST 10%, ECZEMA AREA AND SEVERITY INDEX (EASI) SCORE OF AT LEAST 16, OR PHYSICIAN GLOBAL ASSESSMENT (PGA) SCORE OF AT LEAST 3. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL:12 MONTHS
Other Criteria	INITIAL: PREVIOUS TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING: TOPICAL CORTICOSTEROIDS, TOPICAL CALCINEURIN INHIBITORS [E.G., ELIDEL (PIMECROLIMUS), GENERIC TACROLIMUS OINTMENT], OR TOPICAL PDE4 INHIBITOR [E.G., EUCRISA (CRISABOROLE)].

DURVALUMAB

Products Affected

- Imfinzi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 MONTHS
Other Criteria	N/A

EDARAVONE

Products Affected

- Radicava

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ELBASVIR/GRAZOPREVIR

Products Affected

- Zepatier

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD PUGH B OR C)
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS. FOR GENOTYPE 1A -TESTING FOR NS5A RESISTANCE-ASSOCIATED POLYMORPHISMS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. NO CONCURRENT USE OF SOVALDI AND ANY OF THE FOLLOWING AGENTS: PHENYTOIN, CARBAMAZEPINE, RIFAMPIN, EFAVIRENZ, ATAZANAVIR, DARUNAVIR, LOPINAVIR, SAQUINAVIR, TIPRANAVIR, CYCLOSPORINE, NAFCILLIN, KETOCONAZOLE, MODAFINIL, BOSENTAN, ETRAVIRINE, ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR, ATORVASTATIN AT DOSES GREATER THAN 20MG PER DAY OR ROSUVASTATIN AT DOSES GREATER THAN 10MG PER DAY.</p>

ELIGLUSTAT TARTRATE

Products Affected

- Cerdelga

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ELOSULFASE ALFA

Products Affected

- Vimizim

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	LIFETIME OF MEMBERSHIP IN PLAN.
Other Criteria	

ELOTUZUMAB

Products Affected

- Empliciti

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ELTROMBOPAG

Products Affected

- Promacta

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ITP: INITIAL: 2 MONTHS. RENEWAL: AFTER RESPONSE: 12 MONTHS. AFTER INADEQUATE DOSE:2 MOS. HCV:12 MOS.
Other Criteria	CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA PURPURA (ITP): INITIAL: TRIAL OF OR CONTRAINDICATION TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY. ITP: RENEWAL: PATIENT HAS A CLINICAL RESPONSE AS DEFINED BY AN INCREASE IN PLATELET COUNT OF GREATER THAN OR EQUAL TO 50 X10 ⁹ /L (GREATER THAN OR EQUAL TO 50,000 PER UL) AT THE MAX DOSE OF 75MG PER DAY FOR 4 WEEKS. HEPATITIS C: CONCURRENT INTERFERON THERAPY.

ENASIDENIB

Products Affected

- Idhifa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ENDOTHELIN RECEPTOR ANTAGONISTS

Products Affected

- Letairis
- Opsumit
- Tracleer

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. LETAIRIS: PATIENT DOES NOT HAVE IDIOPATHIC PULMONARY FIBROSIS (IPF) TRACLEER: PATIENT DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASES IN BILIRUBIN BY 2 OR MORE TIMES ULN. PATIENT IS NOT CONCURRENTLY TAKING CYCLOSPORINE A OR GLYBURIDE. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS.

ENZALUTAMIDE

Products Affected

- Xtandi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF OR CONTRAINDICATION TO ZYTIGA (ABIRATERONE ACETATE) IS ALSO REQUIRED IN PATIENTS WHO DO NOT HAVE A CONTRAINDICATION OR INTOLERANCE TO PREDNISONE.

ERLOTINIB

Products Affected

- Tarceva oral tablet 100 mg, 150 mg, 25 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

ERYTHROPOIESIS STIMULATING AGENTS - EPOETIN ALFA

Products Affected

- EPOGEN 10,000 UNITS/ML VIAL SDV, P/F, OUTER
- Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL
- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL OFF LABEL ANEMIA IN HEPATITIS C BEING TREATED IN COMBINATION WITH RIBAVIRIN AND INTERFERON ALFA OR PEGINTERFERON ALFA.
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	<p>INITIAL: CHRONIC RENAL FAILURE (CRF) AND ANEMIA RELATED TO ZIDOVUDINE THERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10G/DL. CANCER CHEMOTHERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10G/DL ANEMIA DUE TO CONCURRENT HEPATITIS C TREATMENT WITH RIBAVIRIN PLUS INTERFERON ALFA/PEGINTERFERON ALFA REQUIRES A HEMOGLOBIN LEVEL LESS THAN 10G/DL AND RIBAVIRIN DOSE REDUCTION (UNLESS CONTRAINDICATED).ELECTIVE NON-CARDIAC OR NON-VASCULAR SURGERY REQUIRES A HEMOGLOBIN LEVEL LESS THAN 13G/DL. RENEWAL: CHRONIC RENAL FAILURE REQUIRES THAT THE PATIENT MEETS ONE OF THE FOLLOWING: IF THE PATIENT IS CURRENTLY RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 11G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 11G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. IF THE PATIENT IS NOT RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 10G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 10G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. ANEMIA DUE TO CONCURRENT HEPATITIS C TREATMENT WITH RIBAVIRIN PLUS INTERFERON ALFA/PEGINTERFERON ALFA, OR ANEMIA DUE TO ZIDOVUDINE THERAPY REQUIRES HEMOGLOBIN LEVELS BETWEEN 10G/DL AND 12G/DL. ANEMIA DUE TO EFFECT OF CONCOMITANTLY ADMINISTERED CANCER CHEMOTHERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10 G/DL OR THAT THE HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	<p>ANEMIA FROM MYELOSUPPRESSIVE CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE:12 MONTHS.SURGERY:1 MO.HCV:6 MOS.</p>

PA Criteria	Criteria Details
Other Criteria	ALL INDICATIONS: TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.

ERYTHROPOIESIS STIMULATING AGENTS - MIRCERA

Products Affected

- Mircera

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC RENAL FAILURE REQUIRES HEMOGLOBIN LEVELS LESS THAN 10G/DL RENEWAL: CHRONIC RENAL FAILURE REQUIRES THAT THE PATIENT MEETS ONE OF THE FOLLOWING: IF THE PATIENT IS CURRENTLY RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 11G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 11G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. IF THE PATIENT IS NOT RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 10G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 10G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ANEMIA DUE TO CKD WITH OR WITHOUT DIALYSIS: 12 MONTHS.
Other Criteria	TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.

ETANERCEPT

Products Affected

- Enbrel subcutaneous recon soln
- Enbrel SureClick
- Enbrel subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING AT LEAST 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS: 18 YEARS OR OLDER
Prescriber Restrictions	RHEUMATOID ARTHRITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. PJIA: 3 MONTHS. PSA/AS/PSO: 4 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA.</p>

ETEPLIRSEN

Products Affected

- Exondys 51

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	PHYSICIAN ATTESTATION OF GENETIC TESTING CONFIRMING THAT MUTATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) GENE IS AMENABLE TO EXON 51 SKIPPING.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST SPECIALIZING IN THE TREATMENT OF DMD AT A DMD TREATMENT CENTER.
Coverage Duration	INITIAL: 24 WEEKS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL CRITERIA: PATIENT IS AMBULATORY AND IS CONCURRENTLY RECEIVING TREATMENT WITH GLUCOCORTICOIDS. RENEWAL CRITERIA: PATIENT HAS MAINTAINED OR DEMONSTRATED A LESS THAN EXPECTED DECLINE IN AMBULATORY ABILITY IN MUSCLE FUNCTION ASSESSMENTS OR OTHER MUSCLE FUNCTION (I.E. PULMONARY OR CARDIAC FUNCTION) DURING THE PAST 24 WEEKS.

EVEROLIMUS

Products Affected

- Afinitor Disperz 7.5 mg
- Afinitor oral tablet 10 mg, 2.5 mg, 5 mg,

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED RENAL CELL CARCINOMA (RCC): TRIAL OF OR CONTRAINDICATION TO SUTENT OR NEXAVAR.

EVOLOCUMAB

Products Affected

- Repatha Pushtronex
- Repatha SureClick
- Repatha Syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	HEFH OR ASCVD: 18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
Coverage Duration	INITIAL: 6 MONTHS RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): MUST HAVE LDL LEVEL GREATER THAN 100MG/DL ON MAXIMAL DRUG TREATMENT (MDT) FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS AND ONE OF THE FOLLOWING: (1) HEFH DETERMINED BY SIMON BROOME DIAGNOSTIC (SBD) CRITERIA OR A SCORE OF 6 OR GREATER ON THE DUTCH LIPID NETWORK (DLN) CRITERIA OR (2) ASCVD AS SUBSTANTIATED BY PHYSICIAN ATTESTATION.</p> <p>HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): LDL LEVEL GREATER THAN 100MG/DL ON MDT FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS AND HOFH DETERMINED BY ONE OF THE FOLLOWING: 1) SBD CRITERIA, 2) A SCORE OF 8 OR GREATER ON THE DLN CRITERIA, OR 3) A CLINICAL DIAGNOSIS BASED ON A HISTORY OF AN UNTREATED LDL-C CONCENTRATION GREATER THAN 500 MG/DL TOGETHER WITH EITHER XANTHOMA BEFORE 10 YEARS OF AGE, OR EVIDENCE OF HEFH IN BOTH PARENTS. NO CONCURRENT USE OF OTHER PCSK9 INHIBITORS. INITIAL THERAPY: FOR STATIN TOLERANT PATIENTS: MUST HAVE TRIED MAXIMALLY TOLERATED DOSE OF HIGH INTENSITY STATIN SUCH AS ATORVASTATIN OR ROSUVASTATIN. FOR STATIN INTOLERANT PATIENTS WITH HEFH OR ASCVD: ONE OF THE FOLLOWING MUST BE MET: PHYSICIAN ATTESTATION OF STATIN INTOLERANCE (INCLUDING BUT NOT LIMITED TO MYOPATHY), OR PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AT ANY DOSE. PATIENTS WITH CONTRAINDICATIONS TO STATINS INCLUDING ACTIVE DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT OR HYPERSENSITIVITY REACTIONS WILL BE APPROVED FOR REPATHA THERAPY WITHOUT DOCUMENTED STATIN INTOLERANCE. FOR STATIN INTOLERANT PATIENTS WITH HOFH: MUST BE ON MAX LIPID-LOWERING THERAPY INCLUDING ONE OF THE FOLLOWING: NIACIN, BILE ACID SEQUESTRANT, LOMITAPIDE OR MIPOMERSEN. QUALIFIERS MUST PROVIDE DOCUMENTATION OF STATIN INTOLERANCE TO ONE OF THE FOLLOWING: A HIGH INTENSITY STATIN (ROSUVASTATIN OR ATORVASTATIN) OR OTHER STATIN THERAPY AT ANY DOSE. STATIN INTOLERANT PATIENTS</p>

PA Criteria	Criteria Details
	<p>MUST BE ON MAXIMAL LIPID-LOWERING MEDICATION (NON-STATIN THERAPY) FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS WITH DOCUMENTATION OF STATIN INTOLERANCE TO ATORVASTATIN OR ROSUVASTATIN OR STATIN THERAPY AT ANY DOSE. DOCUMENTATION OF STATIN INTOLERANCE INCLUDES: (1) PHYSICIAN ATTESTATION, OR (2) PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AND HAS EXPERIENCED SKELETAL MUSCLE RELATED EVENTS (E.G. MYOPATHY). RENEWAL CRITERIA: RECEIVING PRIOR REPATHA THERAPY FOR AT LEAST 6 MONTHS AND NOT ON CONCURRENT THERAPY WITH OTHER PCSK9 INHIBITORS, MIPOMERSEN, OR LOMITAPIDE.</p>

FENTANYL NASAL SPRAY

Products Affected

- Lazanda

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	<p>CANCER: CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION (SUCH AS MORPHINE SULFATE SR, OXYCODONE SR, OR FENTANYL). EITHER A TRIAL OR CONTRAINDICATION TO AT LEAST ONE (1) IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT (SUCH AS MORPHINE SULFATE IR, OXYCODONE/ASPIRIN, OXYCODONE/ACETAMINOPHEN, CODEINE/ACETAMINOPHEN, HYDROMORPHONE, OR MEPERIDINE) OR MEMBER HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES AND TRIAL OR CONTRAINDICATION TO GENERIC FENTANYL CITRATE LOZENGE.</p>

FENTANYL TRANSMUCOSAL AGENTS - FENTANYL CITRATE

Products Affected

- fentanyl citrate

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	CANCER: CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION (SUCH AS MORPHINE SULFATE SR, OXYCODONE SR, OR FENTANYL). EITHER A TRIAL OR CONTRAINDICATION TO AT LEAST ONE (1) IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT (SUCH AS MORPHINE SULFATE IR, OXYCODONE/ASPIRIN, OXYCODONE/ACETAMINOPHEN, CODEINE/ACETAMINOPHEN, HYDROMORPHONE, OR MEPERIDINE) OR MEMBER HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.

FINGOLIMOD

Products Affected

- Gilenya

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

FOLIC ACID OTC

Products Affected

- FOLIC ACID 400 MCG TABLET
S/F,P/F,LACTOSE-FREE

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO FEMALES, AGES 14 THROUGH 45 YEARS, TO PREVENT NEURAL TUBE DEFECTS IN CURRENT AND FUTURE PREGNANCIES ONLY.

GEFITINIB

Products Affected

- Iressa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

GEMTUZUMAB OZOGAMICIN

Products Affected

- Mylotarg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

GLATIRAMER ACETATE

Products Affected

- Copaxone subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

GLECAPREVIR/PIBRENTASVIR

Products Affected

- Mavyret

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.
Exclusion Criteria	MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C)
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED OR CONTRAINDICATED BY THE MANUFACTURER: CARBAMAZEPINE, RIFAMPIN, ETHINYL ESTRADIOL-CONTAINING MEDICATION, ATAZANAVIR, DARUNAVIR, LOPINAVIR, RITONAVIR, EFAVIRENZ, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, OR CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY. PATIENT MUST NOT HAVE PRIOR FAILURE OF A DAA REGIMEN WITH NS5A INHIBITOR AND HCV PROTEASE INHIBITOR.</p>

GLUCOSE TEST STRIPS AND LANCETS

Products Affected

- 1ST CHOICE THIN LANCETS
- 1ST TIER COMFORTOUCH 28G LANCET
- 1ST TIER COMFORTOUCH 30G LANCET
- ACCU-CHEK FASTCLIX LANCETS
- ACCU-CHEK MULTICLIX LANCETS
- ACCU-CHEK SAFE-T-PRO 23G LANCET
- ACCU-CHEK SAFE-T-PRO PLUS 23G
- ACCU-CHEK SOFTCLIX LANCETS
- ACTI-LANCE LITE 28G LANCETS
- ACTI-LANCE SPECIAL 17G LANCETS
- ACTI-LANCE UNIVERS 23G LANCETS
- ADVANCED TRAVEL 28G LANCETS 28G,SINGLE-USE,STRL
- ADVANCED TRAVEL 30G LANCETS
- ADVOCATE 26G LANCETS 26 G,STERILE
- ADVOCATE 26G LANCETS STERILE
- ADVOCATE 30G LANCETS TWIST TOP
- ALTERNATE SITE 26G LANCETS RECAPABLE
- ASSURE COMFORT 30G LANCETS
- ASSURE HAEMOLANCE PLUS 18G
- ASSURE HAEMOLANCE PLUS 21G
- ASSURE HAEMOLANCE PLUS 25G
- ASSURE HAEMOLANCE PLUS 28G
- ASSURE LANCE 25G LANCETS
- ASSURE LANCE 28G LANCETS
- ASSURE LANCE PLUS 21G LANCETS
- ASSURE LANCE PLUS 25G LANCETS
- ASSURE LANCE PLUS 30G LANCETS
- BD LANCETS 33G
- BD MICROTAINER 21G LANCETS
- BD MICROTAINER 30G LANCETS
- BD ULTRA-FINE 33G LANCETS
- BD ULTRA-FINE II 30G LANCETS
- BLOOD LANCETS 30G EASY TWIST
- BULLSEYE MINI SAFETY 21G
- BULLSEYE MINI SAFETY 25G LANCET
- CAREONE ULTRA THIN LANCET
- CARESENS ULTRA THIN 30G LANCET
- CARETOUCH TWIST 28G LANCET
- CARETOUCH TWIST 30G LANCET
- CLEVER CHEK ULTRA THIN 30G
- COAGUCHEK LANCETS
- COMFORT EZ SAFETY 21G LANCETS
- COMFORT EZ SAFETY 23G LANCETS
- COMFORT EZ SAFETY 28G LANCETS
- COMFORT LANCETS
- CVS MICRO THIN 33G LANCETS UNIVERSAL 1
- CVS THIN 26G LANCETS
- CVS ULTRA THIN 30G LANCETS
- DROPLET 30G LANCETS
- E-Z JECT LANCETS
- E-ZJECT COLOR 32G LANCETS
- E-ZJECT COLOR 33G LANCETS
- E-ZJECT SUPER THIN 30G LANCETS SUPER THIN
- EASY COMFORT 30G LANCETS 30G,TWIST TOP,STRL
- EASY TOUCH 28G LANCETS 28G,PULL TOP,STERILE
- EASY TOUCH SAFETY 21G LANCETS
- EASY TOUCH SAFETY 23G LANCETS
- EASY TOUCH SAFETY 26G LANCETS
- EASY TOUCH TWIST 28G LANCETS
- EASY TOUCH TWIST 30G LANCETS
- EASY TOUCH TWIST 32G LANCETS

- EASY TOUCH TWIST 33G LANCETS
- EASY TWIST & CAP 28G LANCETS
- EMBRACE 30G LANCETS
- EZ SMART 28G LANCETS
- FIFTY50 SAFETY SEAL 30G LANCET
- FIFTY50 SAFETY SEAL 32G LANCET
- FINE 30 UNIVERSAL 30G LANCETS
- FINGERSTIX LANCETS
- FORA 30G LANCETS TWIST OFF,SINGLE USE
- FORACARE 30G LANCETS
- FREESTYLE 28G LANCETS
- FREESTYLE UNISTIK 2 LANCETS
- GLUCOCOM 28G LANCETS
- GLUCOCOM 30G LANCETS
- GLUCOCOM 33G LANCETS
- GMATE 30G LANCETS
- GNP UNIVERSAL 1 STANDARD 21G
- GNP UNIVERSAL 1 SUPER THIN 30G
- HEALTHY ACCENTS UNILET 30G
- INCONTROL SUPER THIN 30G LANCET
- INCONTROL ULTRA THIN 28G LANCET
- INJECT EASE 28G LANCETS
- INJECT EASE 30G LANCETS
- INVACARE 30G LANCETS
- KINNEY BRAND 23G LANCETS
- KRO UNIVERSAL 1 THIN 26G LANCET
- KROGER SUPER THIN LANCETS
- LANCETS THIN 23G
- LANCETS ULTRA THIN 26G
- LITE TOUCH 30G LANCETS
- LITE TOUCH 33G LANCETS
- LONGS THIN LANCETS 30G 30G
- MEDISENSE THIN 28G LANCETS
- MEDLANCE PLUS 21G LANCETS UNIVERSAL, 1.8MM
- MEDLANCE PLUS 30G LANCETS SUPERLITE, 1.2MM
- MEDLANCE PLUS LITE 25G LANCETS STERILE, 1.5MM
- MICROLET LANCETS
- MONOLET 21G LANCETS
- MONOLET THIN 28G LANCETS
- MYGLUCOHEALTH 30G LANCETS
- NOVA SAFETY 23G LANCETS
- NOVA SAFETY 28G LANCETS
- NOVA SUREFLEX THIN LANCETS
- ON CALL 30G LANCET
- ON CALL PLUS 30G LANCET
- ONE TOUCH DELICA 33G LANCETS
- ONETOUCH DELICA 30G LANCETS
- ONETOUCH DELICA 33G LANCETS
- ONETOUCH SURESOFT LANCING DEV
- ONETOUCH ULTRASOFT LANCETS
- PHARMACIST CHOICE 30G LANCETS ULTRA THIN
- PRESSURE ACTIVATED 21G LANCETS
- PRESSURE ACTIVATED 28G LANCETS
- PRO COMFORT 30G LANCETS
- PRO COMFORT 31G LANCET
- PRODIGY PRESSURE ACTIVATED 28G
- PRODIGY SAFETY 26G LANCETS
- PRODIGY TWIST TOP 28G LANCET
- PUSH BUTTON SAFETY 21G LANCET
- PUSH BUTTON SAFETY 28G LANCET
- QC UNILET SUPER THIN 30G LANCET
- RA E-ZJECT 26G LANCETS
- RA E-ZJECT 28G LANCETS
- READYLANCE 21G SAFETY LANCETS
- READYLANCE 23G SAFETY LANCETS
- READYLANCE 26G SAFETY LANCETS
- READYLANCE 28G SAFETY LANCETS
- READYLANCE 30G SAFETY LANCETS
- RELIAMED 30G LANCETS
- RELIAMED SAFETY 23G LANCETS

- RELIAMED SAFETY 28G LANCETS LATEX-FREE
- RELIAMED SAFETY SEAL 28G LANCET
- RELIAMED SAFETY SEAL 30G LANCET
- RELION THIN 26G LANCETS
- RELION ULTRA THIN PLUS 33G
- RELION ULTRA THIN PLUS LANCETS
- RIGHTEST GL300 30G LANCETS
- SAFETY 21G LANCETS LATEX-FREE
- SAFETY 28G LANCETS LATEX-FREE
- SAFETY LANCETS 26G
- SAFETY SEAL 28G LANCETS
- SAFETY SEAL 30G LANCETS
- SAFETY-LET 30G LANCETS
- SB LANCETS THIN 28G
- SHOPKO ON-THE-GO 30G LANCETS GENTLE
- SINGLE-LET LANCETS
- SM COLOR LANCETS 21G
- SM LANCETS 21G
- SM THIN LANCETS 26G
- SMART SENSE COLOR 33G LANCETS
- SMART SENSE STANDARD 21G
- SMART SENSE THIN 26G LANCETS
- SMARTEST LANCET
- SOFT TOUCH LANCETS
- SOLUS V2 28G LANCETS
- SOLUS V2 30G TWIST LANCETS
- STERILANCE TL TWIST 30G LANCET
- STERILANCE TL TWIST 32G LANCET
- SUPER THIN 28G LANCETS STERILE
- SUPER THIN 33G LANCETS
- SURE COMFORT 18G LANCETS
- SURE COMFORT 21G LANCETS
- SURE COMFORT 23G LANCETS
- SURE COMFORT 28G LANCETS
- SURE COMFORT 30G LANCETS
- SURE-LANCE 26G LANCETS
- SURE-LANCE FLAT LANCETS
- SURE-LANCE THIN 28G LANCETS
- SURE-LANCE ULTRA THIN 30G
- SURE-TOUCH LANCET
- TECHLITE 28G LANCETS
- TECHLITE 30G LANCETS
- TELCARE ULTRA THIN 30G LANCETS
- THIN LANCETS 28G
- TOPCARE UNIVERSAL1 33G LANCETS
- TOPCARE UNIVERSAL1 THIN LANCET ULTRA THIN, 30G
- TRUEPLUS 26G LANCETS
- TRUEPLUS 33G LANCETS
- TRUEPLUS SAFETY 28G LANCETS 28G, STERILE
- TRUEPLUS SUPER THIN 28G LANCET 28G, STERILE
- TRUEPLUS ULTRA THIN 30G LANCET
- ULTILET 28G LANCETS
- ULTILET 30G LANCETS
- ULTILET 33G LANCETS
- ULTILET BASIC 30G LANCETS
- ULTILET CLASSIC 26G LANCETS
- ULTILET CLASSIC 28G LANCETS
- ULTILET CLASSIC 30G LANCETS
- ULTILET CLASSIC 33G LANCETS
- ULTILET SAFETY 23G LANCETS
- ULTRA THIN 28G LANCETS ULTRA THIN
- ULTRA THIN 30G LANCETS STERILE
- ULTRA THIN 31G LANCETS
- ULTRA THIN 33G LANCETS
- ULTRA-THIN II 26G LANCET
- ULTRA-THIN II 28G LANCETS
- ULTRA-THIN II 30G LANCETS
- ULTRALANCE 26G LANCETS
- ULTRALANCE 28G LANCETS
- ULTRATLC LANCETS
- UNILET COMFORTOUCH 26G LANCETS
- UNILET COMFORTOUCH LANCET
- UNILET EXCELITE II LANCET

- UNILET EXCELITE LANCET
- UNILET GP LANCET
- UNILET LANCET SUPERLITE
- UNILET MICRO THIN 33G LANCETS
- UNILET ULTRA THIN 28G LANCETS
- UNISTIK 3 COMFORT LANCET
- UNISTIK 3 EXTRA 21G LANCETS
- UNISTIK 3 GENTLE ON-THE-GO 30G
- UNISTIK 3 NORMAL 23G LANCETS
- UNISTIK 3 SAFETY 21G LANCETS
- UNISTIK CZT COMFORT 28G LANCET
- UNISTIK CZT NORMAL 23G LANCETS
- UNISTIK SAFETY 28G LANCET
- UNISTIK SAFETY 30G LANCETS
- UNISTIK TOUCH 21G LANCETS
- UNISTIK TOUCH 23G LANCETS
- UNISTIK TOUCH 28G LANCETS
- UNISTIK TOUCH 30G LANCETS
- UNIVERSAL 1 33G LANCETS FOR MEIJER
- WALGREENS ULTRA THIN LANCETS

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A

PA Criteria	Criteria Details
Other Criteria	<p>COVERAGES OF BLOOD GLUCOSE TEST STRIPS AND LANCETS MAY BE PROVIDED WITH A WRITTEN PRESCRIPTION BY A LICENSED PRACTITIONER TO INPATIENTS RECEIVING NURSING FACILITY LEVEL A (NF-A) SERVICES OR NURSING FACILITY LEVEL B (NF-B) SERVICES, WHETHER OR NOT IN A HOSPITAL SETTING. BLOOD GLUCOSE TEST STRIPS AND LANCETS ARE RESTRICTED TO PATIENTS WITH A DIABETES DIAGNOSIS. BLOOD GLUCOSE TEST STRIPS AND LANCETS PROVIDED TO INPATIENTS RECEIVING INPATIENT HOSPITAL SERVICES ARE NOT COVERED. REQUESTS THAT DO NOT MEET THE NURSING FACILITY LEVEL A OR LEVEL B CRITERIA WILL BE REVIEWED FOR PART B COVERAGE.</p>

GLYCEROL PHENYL BUTYRATE

Products Affected

- Ravicti

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF OR CONTRAINDICATION TO SODIUM PHENYL BUTYRATE (BUPHENYL).

GOLIMUMAB IV

Products Affected

- Simponi ARIA

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PREVIOUS TRIAL HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA.

GOLIMUMAB SQ

Products Affected

- Simponi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. ULCERATIVE COLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. PSA/AS: 4 MONTHS. UC: 12 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING REFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA OR COSENTYX. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING CONVENTIONAL AGENTS SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE.

GUSELKUMAB

Products Affected

- Tremfya

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA.

HIGH RISK DRUGS IN THE ELDERLY - ANTICHOLINERGICS - BENZTROPINE_TRIHEXYPHENIDYL

Products Affected

- benztropine oral
- trihexyphenidyl

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PREScriBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - ANTICHOLINERGICS - PROMETHAZINE

Products Affected

- Phenadoz
- promethazine oral
- promethazine rectal
- Promethegan

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRURITUS/URTICARIA/SEASONAL/PERENNIAL ALLERGY: TRIAL OF OR CONTRAINDICATION TO A NON-SEDATING ANTIHISTAMINE SUCH AS LEVOCETIRIZINE. NAUSEA AND VOMITING: PRESCRIBER ACKNOWLEDGEMENT OR AWARENESS THAT THE REQUESTED MEDICATION IS LABELED AS A HIGH-RISK MEDICATION FOR PATIENTS 65 YEARS AND OLDER. MOTION SICKNESS: TRIAL OF OR CONTRAINDICATION TO MECLIZINE. HOSPICE PATIENTS WILL BE APPROVED WITHOUT TRIAL OF FORMULARY ALTERNATIVES NOR REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - ANTI- INFECTIVE

Products Affected

- nitrofurantoin macrocrystal
- nitrofurantoin monohyd/m-cryst

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF (UNLESS CONTRAINDICATED TO) SULFAMETHOXAZOLE/TRIMETHOPRIM (TMP-SMX) OR TRIMETHOPRIM. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING A TRIAL OF SULFAMETHOXAZOLE/TRIMETHOPRIM (TMP-SMX) OR TRIMETHOPRIM.

HIGH RISK DRUGS IN THE ELDERLY - BARBITURATE COMBINATIONS

Products Affected

- Allzital
- Ascomp with Codeine
- Butalbital Compound W/Codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen oral tablet 50-325 mg
- butalbital-acetaminophen-caff oral capsule 50-325-40 mg
- butalbital-acetaminophen-caff oral tablet 50-325-40 mg
- butalbital-aspirin-caffeine
- Capacet
- Margesic
- Tencon oral tablet 50-325 mg
- Zebutal oral capsule 50-325-40 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - CARDIOVASCULAR

Products Affected

- guanfacine oral tablet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS
Prescriber Restrictions	
Coverage Duration	12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>HYPERTENSION: TRIAL OR CONTRAINDICATION TO TWO (2) OF THE FOLLOWING - BENAZEPRIL, BENAZEPRIL/HYDROCHLOROTHIAZIDE, CAPTOPRIL, CAPTOPRIL/HYDROCHLOROTHIAZIDE, ENALAPRIL, ENALAPRIL/HYDROCHLOROTHIAZIDE, FOSINOPRIL, FOSINOPRIL/HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL/HYDROCHLOROTHIAZIDE, QUINAPRIL, QUINAPRIL/HYDROCHLOROTHIAZIDE, RAMIPRIL, MOEXIPRIL, MOEXIPRIL/HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, TRANDOLAPRIL, TRANDOLAPRIL/VERAPAMIL, LOSARTAN, LOSARTAN/HYDROCHLOROTHIAZIDE, IRBESARTAN, IRBESARTAN/HYDROCHLOROTHIAZIDE, OLMESARTAN, OLMESARTAN/HYDROCHLOROTHIAZIDE, OLMESARTAN/AMLODIPINE/HYDROCHLOROTHIAZIDE, VALSARTAN, VALSARTAN/HYDROCHLOROTHIAZIDE, DILTIAZEM HCL, DILTIAZEM SUSTAINED RELEASE, VERAPAMIL, VERAPAMIL SUSTAINED RELEASE, ATENOLOL, ATENOLOL/CHLORTHALIDONE, BISOPROLOL, BISOPROLOL/HYDROCHLOROTHIAZIDE, CARVEDILOL, METOPROLOL TARTRATE, NADOLOL, ACEBUTOLOL, BETAXOLOL, LABETALOL, METOPROLOL SUCCINATE, METOPROLOL/HYDROCHLOROTHIAZIDE, PINDOLOL, PROPRANOLOL, PROPRANOLOL/HYDROCHLOROTHIAZIDE, SOTALOL, TIMOLOL MALEATE. HOSPICE PATIENTS ARE APPROVED WITHOUT A TRIAL OF FORMULARY ALTERNATIVES.</p>

HIGH RISK DRUGS IN THE ELDERLY - CENTRAL NERVOUS SYSTEM - THIORIDAZINE

Products Affected

- thioridazine

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	SCHIZOPHRENIA - PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - DIGOXIN

Products Affected

- Digitek
- Digox
- DIGOXIN 0.25 MG/ML SYRINGE
- digoxin injection solution
- digoxin oral solution 50 mcg/mL
- digoxin oral tablet
- Lanoxin oral tablet 187.5 mcg, 62.5 mcg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DIGOXIN LEVEL
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	APPROVAL FOR MEMBERS STABLE ON DOSES GREATER THAN 125 MCG PER DAY WITH DOCUMENTED THERAPEUTIC DIGOXIN LEVEL TAKEN WITHIN THE PAST YEAR. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING DIGOXIN LEVELS.

HIGH RISK DRUGS IN THE ELDERLY - ENDOCRINE - ESTROGEN

Products Affected

- CombiPatch
- Duavee
- estradiol oral
- estradiol transdermal patch semiweekly
- estradiol transdermal patch weekly
- estradiol-norethindrone acet
- estropipate
- Menest
- Mimvey
- Mimvey Lo
- Premarin oral
- Premphase
- Prempro

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VULVAR/VAGINAL ATROPHY, OSTEOPOROSIS AND VASOMOTOR SYMPTOMS OF MENOPAUSE: PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS LABELED AS HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. ALL OTHER FDA APPROVED INDICATIONS NOT PREVIOUSLY MENTIONED IN THIS SECTION, SUCH AS PALLIATIVE TREATMENT, AND HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - ENDOCRINE - SULFONYLUREAS

Products Affected

- glyburide
- glyburide-metformin
- glyburide micronized

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF GLIMEPIRIDE, GLIPIZIDE, OR PRESCRIBER ACKNOWLEDGEMENT/ AWARENESS THAT THE DRUG IS LABELED AS HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT A TRIAL OF FORMULARY ALTERNATIVES.

HIGH RISK DRUGS IN THE ELDERLY - NON-BENZODIAZEPINE

Products Affected

- eszopiclone
- zolpidem oral
- zaleplon

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF SILENOR AND ROZEREM OR PRESCRIBER ACKNOWLEDGEMENT/ AWARENESS THAT THE DRUG IS LABELED AS HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING A TRIAL OF FORMULARY ALTERNATIVES (SILENOR AND ROZEREM) OR PRESCRIBER ACKNOWLEDGEMENT.

HIGH RISK DRUGS IN THE ELDERLY - SKELETAL MUSCLE RELAXANTS

Products Affected

- carisoprodol
- chlorzoxazone oral tablet 500 mg
- cyclobenzaprine oral tablet 10 mg, 5 mg
- Metaxall
- metaxalone
- methocarbamol oral

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

HYDROXYPROGESTERONE CAPROATE- DELALUTIN GENERIC

Products Affected

- hydroxyprogesterone caproate

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IBRUTINIB

Products Affected

- Imbruvica

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IDELALISIB

Products Affected

- Zydelig

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IMATINIB MESYLATE

Products Affected

- imatinib oral tablet 100 mg, 400 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ALL DIAGNOSES:12 MOS.ADJUVANT GASTROINTESTINAL STROMAL TUMOR(GIST)TREATMENT(TWICE DAILY DOSE):36 MOS
Other Criteria	GASTROINTESTINAL STROMAL TUMOR (GIST) KIT (CD117) POSITIVE USE IMATINIB 400MG TWICE DAILY: TRIAL OF IMATINIB 400MG ONCE DAILY OR GIST TUMOR EXPRESSING A KIT EXON 9 MUTATION. PREVIOUSLY TREATED CML REQUIRES BCR-ABL MUTATIONAL ANALYSIS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, V299L, F317L/V/I/C, Y253H, E255K/V, F359V/C/I.

IMIQUIMOD - ALDARA

Products Affected

- imiquimod

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACTINIC KERATOSIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST . SUPERFICIAL BASAL CELL CARCINOMA: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR AN ONCOLOGIST.
Coverage Duration	4 MONTHS
Other Criteria	EXTERNAL GENITAL WARTS: TRIAL OF PODOFILOX (CONDYLOX) 0.5% TOPICAL SOLUTION. ACTINIC KERATOSIS BRAND DRUG REQUEST: TRIAL OF GENERIC IMIQUIMOD 5% CREAM. SUPERFICIAL BASAL CELL CARCINOMA: LESS THAN 2CM IN SIZE AND NOT ON THE FACE.

INFLIXIMAB

Products Affected

- Remicade

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: GASTROENTEROLOGIST.
Coverage Duration	INITIAL: CD/UC: 8 MO. RA: 6 MO. PSA/AS/PSO: 4 MO. RENEWAL FOR ALL INDICATIONS: 12 MO.

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: SIMPONI OR ENTYVIO.</p>

INFLIXIMAB-ABDA

Products Affected

- Renflexis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ALL INDICATIONS: 6 MO.
Other Criteria	

INFLIXIMAB-DYYB

Products Affected

- Inflectra

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECT THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: GASTROENTEROLOGIST.
Coverage Duration	INITIAL: CD/UC: 8 MOS. RA: 6 MOS. PSA/AS/PSO: 4 MOS. RENEWAL FOR ALL INDICATIONS: 12 MOS.

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY CIMZIA. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: SIMPONI OR ENTYVIO.</p>

INOTUZUMAB OZOGAMICIN

Products Affected

- Besponsa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

INTERFERON ALFA-2B

Products Affected

- Intron A injection

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HEPATITIS C: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST). NO REQUIREMENT FOR OTHER FDA APPROVED INDICATIONS.
Coverage Duration	6 MONTHS
Other Criteria	LIMITED TO 1 YEAR OF THERAPY EXCEPT 18 MONTHS FOR FOLLICULAR LYMPHOMA. HEPATITIS C GENOTYPE 1, 2, 3, 4, 5, OR 6: REQUIRES A TRIAL OF OR CONTRAINDICATION TO PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B USED IN COMBINATION WITH RIBAVIRIN UNLESS CONTRAINDICATED.

INTERFERONS FOR MS-AVONEX, PLEGRIDY, REBIF

Products Affected

- Avonex (with albumin)
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit
- Plegridy
- Rebif (with albumin)
- Rebif Rebidose
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

INTERFERONS FOR MS-BETASERON, EXTAVIA

Products Affected

- Betaseron subcutaneous kit
- Extavia subcutaneous kit

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	TRIAL WITH TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, AND GLATIRAMER
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IPILIMUMAB

Products Affected

- Yervoy

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: UNRESECTABLE/METASTATIC MELANOMA: 3 MO ADJVNT MELANOMA: 6 MO RENEWAL: ADJVNT MELANOMA: 6 MO
Other Criteria	RENEWAL FOR ADJUVANT MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS)

IVACAFTOR

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE.
Required Medical Information	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS.
Age Restrictions	6 YEARS OF AGE OR OLDER.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IVACAFTOR - GRANULE PACKETS

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	F508DEL MUTATION IN CFTR GENE.
Required Medical Information	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. PATIENT WEIGHT.
Age Restrictions	2 YEARS OF AGE TO 5 YEARS OF AGE
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IXAZOMIB

Products Affected

- Ninlaro

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

IXEKIZUMAB

Products Affected

- TALTZ 80 MG/ML AUTOINJECTOR P/F,L/F,SDV,OUTER
- Taltz Autoinjector (3 Pack)

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	PLAQUE PSORIASIS (PSO): MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PLAQUE PSORIASIS (PSO): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST
Coverage Duration	PLAQUE PSORIASIS (PSO): INITIAL: 4 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	PSORIASIS (PSO): INITIAL PLAQUE : PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA.

LEDIPASVIR-SOFOSBUVIR

Products Affected

- Harvoni

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, SIMEPREVIR, SOFOSBUVIR (AS A SINGLE AGENT), STRIBILD (ELVITAGRAVIR/COBICISTAT/EMTRICITABINE /TENOFVIR), OR TIPRANA VIR/RITONAVIR.

LENALIDOMIDE

Products Affected

- Revlimid

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

LENVATINIB MESYLATE

Products Affected

- Lenvima

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

LIDOCAINE

Products Affected

- lidocaine topical adhesive patch,medicated

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL COVERAGE CONSIDERATION FOR DIABETIC NEUROPATHY.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

LIDOCAINE OINTMENT TIRF

Products Affected

- lidocaine topical ointment

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 MONTHS
Other Criteria	

LOMITAPIDE

Products Affected

- Juxtapid oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 5 mg, 60 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	MODERATE OR SEVERE HEPATIC IMPAIRMENT OR ACTIVE LIVER DISEASE
Required Medical Information	LDL CHOLESTEROL LEVEL, LDL RECEPTOR STATUS
Age Restrictions	AT LEAST 18 YEARS OF AGE OR OLDER
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST.
Coverage Duration	INITIAL: 7 MONTHS RENEWAL: 6 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING: SIMON BROOME DIAGNOSTIC CRITERIA (DEFINITE), (E.G. GENETIC TESTING CONSISTENT WITH HOFH AND PRETREATMENT BASELINE LDL CHOLESTEROL IS GREATER THAN 190 MG/DL), CASCADE SCREENING, DUTCH LIPID NETWORK CRITERIA WITH A SCORE OF AT LEAST 6, OR HISTORY OF UNTREATED CHOLESTEROL GREATER THAN 500MG/DL (OR TREATED CHOLESTEROL GREATER THAN 300MG/DL) AND CUTANEOUS XANTHOMA BEFORE 10 YEARS OF AGE. LOMITAPIDE WILL NOT BE APPROVED FOR PATIENTS CONCURRENTLY USING ANY OF THE FOLLOWING STRONG OR MODERATE CYP3A4 MEDICATIONS: CLARITHROMYCIN, CONIVAPTAN, INDINAVIR, ITRACONAZOLE, KETOCONAZOLE, LOPINAVIR/RITONAVIR, MIBEFRADIL, NEFAZODONE, NELFINAVIR, POSACONAZOLE, RITONAVIR, SAQUINAVIR, TELITHROMYCIN, TIPRANAVIR/RITONAVIR, VORICONAZOLE, AMPRENAVIR, APREPITANT, ATAZANAVIR, CIPROFLOXACIN, CRIZOTINIB, DARUNAVIR/RITONAVIR, DILTIAZEM, ERYTHROMYCIN, FLUCONAZOLE, FOSAMPRENAVIR, IMATINIB, OR VERAPAMIL. INITIAL: LDL CHOLESTEROL LEVEL OF AT LEAST 160MG/DL WHILE ON LIPID-LOWERING THERAPY PRIOR TO INITIATING LOMITAPIDE. PREVIOUS TRIAL OF A PCSK9 INHIBITOR (E.G. ALIROCUMAB OR EVOLOCUMAB), UNLESS THE PATIENT HAS NON-FUNCTIONING LDL RECEPTORS. PREVIOUS TRIAL OF ROSUVASTATIN OR ATORVASTATIN, UNLESS THE PATIENT HAS AN ABSOLUTE CONTRAINDICATION TO STATIN THERAPY (E.G. ACTIVE, DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT, HYPERSENSITIVITY REACTION). STATIN-TOLERANT PATIENTS MUST BE TAKING ATORVASTATIN OR ROSUVASTATIN FOR THE PAST 2 MONTHS PRIOR TO STARTING LOMITAPIDE. LOMITAPIDE MUST BE USED IN COMBINATION WITH ATORVASTATIN OR ROSUVASTATIN. IF THE PATIENT HAS PREVIOUSLY TRIED ATORVASTATIN OR ROSUVASTATIN, LOMITAPIDE MUST BE USED IN COMBINATION WITH ANOTHER STATIN OR LDL-LOWERING AGENT (E.G. BILE ACID SEQUESTRANT, GEMFIBROZIL OR OTHER FIBRATE, EZETIMIBE, OR NIACIN). STATIN-INTOLERANT PATIENTS REQUIRE EITHER PHYSICIAN ATTESTATION OF STATIN</p>

PA Criteria	Criteria Details
	<p>INTOLERANCE OR HISTORY OF SKELETAL-MUSCLE RELATED SYMPTOMS (E.G. MYOPATHY) DUE TO A PREVIOUS TRIAL OF STATINS (E.G. ROSUVASTATIN OR ATORVASTATIN). FOR STATIN-INTOLERANT PATIENTS, LOMITAPIDE MUST BE USED IN COMBINATION WITH ONE OF THE FOLLOWING LIPID-LOWERING TREATMENTS: EZETIMIBE, FENOFIBRATE, NIACIN, OR A BILE ACID SEQUESTRANT (E.G. CHOLESTYRAMINE, COLESTIPOL, COLESEVELAM). RENEWAL: PATIENT HAS RECEIVED AT LEAST 6 MONTHS OF THERAPY WITH LOMITAPIDE IN COMBINATION WITH ANOTHER LIPID-LOWERING AGENT.</p>

LUMACAFTOR-IVACAFTOR

Products Affected

- Orkambi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. BASELINE FEV1.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL 12 MONTHS.
Other Criteria	RENEWAL: MAINTAINED OR IMPROVEMENT IN FEV1 OR REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS OR IMPROVEMENT IN BODY MASS INDEX (BMI).

MEPOLIZUMAB

Products Affected

- Nucala

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	CONCURRENT USE OF XOLAIR
Required Medical Information	BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 150 CELLS/MCL WITHIN THE LAST 6 WEEKS OR GREATER THAN OR EQUAL TO 300 CELLS/MCL WITHIN THE LAST 12 MONTHS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY MEDICINE, AN ALLERGIST OR AN IMMUNOLOGIST.
Coverage Duration	INITIAL 24 WEEKS. RENEWAL 12 MONTHS
Other Criteria	INITIAL THERAPY: PATIENT CURRENTLY TREATED WITH A MAXIMALLY TOLERATED DOSE OF INHALED CORTICOSTEROIDS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION WHICH INCLUDES ANY OF THE FOLLOWING: LONG-ACTING INHALED BETA2-AGONIST, LONG-ACTING MUSCARINIC ANTAGONIST, A LEUKOTRIENE RECEPTOR ANTAGONIST, THEOPHYLLINE, OR ORAL CORTICOSTEROID. RENEWAL REQUIRES DOCUMENTATION THAT THE PATIENT HAS EXPERIENCED IMPROVEMENT IN ASTHMA EXACERBATIONS FROM BASELINE (PHYSICIAN ATTESTATION) AND A REDUCTION IN ORAL CORTICOSTEROID DOSE (IF THE PATIENT WAS ON A MAINTENANCE REGIMEN OF ORAL CORTICOSTEROIDS AT THE INITIATION OF TREATMENT).

METHYLNALTREXONE

Products Affected

- Relistor subcutaneous solution
- Relistor subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	ADVANCED ILLNESS: OPIOID-INDUCED CONSTIPATION. CHRONIC NON-CANCER PAIN: THE PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS FOR PATIENTS RECEIVING PALLIATIVE CARE, 12 MONTHS FOR PATIENTS WITH CHRONIC, NON-CANCER PAIN.
Other Criteria	ADVANCED OR TERMINAL ILLNESS: PATIENT IS RECEIVING PALLIATIVE CARE. CHRONIC NON-CANCER PAIN: PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS AND HAD A PREVIOUS TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK) OR LUBIPROSTONE (AMITIZA).

METHYLNALTREXONE ORAL

Products Affected

- Relistor oral

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS AND HAD A PREVIOUS TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK) OR LUBIPROSTONE (AMITIZA).

MIDOSTAURIN

Products Affected

- Rydapt

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	ACUTE MYELOID LEUKEMIA: 6 MONTHS. AGGRESSIVE SYSTEMIC MASTOCYTOSIS: 12 MONTHS
Other Criteria	N/A

MIFEPRISTONE

Products Affected

- Korlym

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

MIPOMERSEN

Products Affected

- Kynamro

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	LDL CHOLESTEROL LEVEL, LDL RECEPTOR STATUS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
Coverage Duration	INITIAL: 7 MONTHS RENEWAL 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>DIAGNOSIS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS DETERMINED BY ONE OF THE FOLLOWING CRITERIA: SIMON BROOME DIAGNOSTIC CRITERIA (DEFINITE) [EXAMPLE: GENETIC TESTING CONSISTENT WITH HOFH AND PRETREATMENT BASELINE LDL CHOLESTEROL IS GREATER THAN 190 MG/DL], CASCADE SCREENING, DUTCH LIPID NETWORK CRITERIA WITH A SCORE AT LEAST 6, OR HISTORY OF UNTREATED CHOLESTEROL GREATER THAN 500MG/DL (OR TREATED GREATER THAN 300MG/DL) AND CUTANEOUS XANTHOMA BEFORE AGE 10 INITIAL CRITERIA: CURRENT LDL CHOLESTEROL LEVEL IS AT LEAST 160MG/DL. PATIENT DOES NOT HAVE ANY OF THE FOLLOWING CONTRAINDICATIONS TO KYNAMRO (MIPOMERSEN): MODERATE OR SEVERE HEPATIC IMPAIRMENT OR ACTIVE LIVER DISEASE, INCLUDING UNEXPLAINED PERSISTENT ELEVATIONS OF SERUM TRANSAMINASES. PREVIOUS TRIAL OF A PCSK9 INHIBITOR (SUCH AS ALIROCUMAB OR EVOLOCUMAB) UNLESS THE PATIENT HAS NON-FUNCTIONING LDL RECEPTORS. PREVIOUS TRIAL WITH ONE OF THE FOLLOWING STATINS: ROSUVASTATIN OR ATORVASTATIN. PATIENTS WITH ABSOLUTE CONTRAINDICATION TO STATIN THERAPY (ACTIVE, DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT, HYPERSENSITIVITY REACTION) WILL BE APPROVED FOR THERAPY WITHOUT REQUIREMENT OF A TRIAL WITH A STATIN. STATIN-TOLERANT PATIENTS: PRIOR TO (KYNAMRO), PATIENT MUST HAVE BEEN TAKING ONE OF THE FOLLOWING: ATORVASTATIN OR ROSUVASTATIN, FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS. FOR STATIN-INTOLERANT PATIENTS: DOCUMENTATION OF STATIN INTOLERANCE WHICH INCLUDES THE FOLLOWING: PHYSICIAN ATTESTATION OR PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AND HAS EXPERIENCED SKELETAL-MUSCLE RELATED SYMPTOMS (E.G., MYOPATHY). UNLESS CONTRAINDICATED, PATIENT MUST BE ON CONCURRENT THERAPY WITH ONE OF THE FOLLOWING LIPID-LOWERING TREATMENTS (SUCH AS A STATIN [SIMVASTATIN, ATORVASTATIN], EZETIMIBE, FENOFIBRATE, NIACIN, OR BILE ACID SEQUESTRANT [CHOLESTYRAMINE, COLESTIPOL, COLESEVELAM]). RENEWAL CRITERIA:</p>

PA Criteria	Criteria Details
	PATIENT HAS RECEIVED THERAPY FOR AT LEAST 6 MONTHS AND MUST ALSO BE TAKING KYNAMRO IN COMBINATION WITH ANOTHER LIPID-LOWERING AGENT.

NATALIZUMAB

Products Affected

- Tysabri

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CROHN'S DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST.
Coverage Duration	MULTIPLE SCLEROSIS: 12 MONTHS. CROHN'S DISEASE: INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MULTIPLE SCLEROSIS: PREVIOUS TRIAL OF TWO OF THE FOLLOWING PREFERRED AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR GLATIRAMER. CROHN'S DISEASE: PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA. NOT APPROVED FOR PATIENTS ON CONCURRENT THERAPY WITH A TNF (TUMOR NECROSIS FACTOR) INHIBITOR: ENBREL, CIMZIA, REMICADE, SIMPONI OR SIMPONI ARIA

NECITUMUMAB

Products Affected

- Portrazza

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

NERATINIB MALEATE

Products Affected

- Nerlynx

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

NILOTINIB

Products Affected

- Tasigna

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREVIOUSLY TREATED CML REQUIRES BCR-ABL MUTATIONAL ANALYSIS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, Y253H, E255K/V, AND F359V/C/I.

NINTEDANIB ESYLATE

Products Affected

- Ofev

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	NOT APPROVED FOR PATIENTS WITH OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, AND CANCER. NOT APPROVED IF PATIENT DOES NOT HAVE A PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50 PERCENT OR HAS NOT OBTAINED LIVER FUNCTION TESTS.
Required Medical Information	A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST
Coverage Duration	12 MONTHS
Other Criteria	

NIRAPARIB TOSYLATE

Products Affected

- Zejula

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 MONTHS
Other Criteria	N/A

NIVOLUMAB

Products Affected

- Opdivo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: OPDIVO IS NOT APPROVED FOR COMBINATION THERAPY WITH TAFINLAR, MEKINIST (TRAMETINIB), COTELLIC (COBIMETINIB), OR ZELBORAF.

OBETICHOLIC ACID

Products Affected

- Ocaliva

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	PATIENTS WITH COMPLETE BILIARY OBSTRUCTION.
Required Medical Information	
Age Restrictions	18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

OBINUTUZUMAB

Products Affected

- Gazyva

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	

OCRELIZUMAB

Products Affected

- Ocrevus

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS: TRIAL OF TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR GLATIRAMER. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

OLAPARIB

Products Affected

- Lynparza oral capsule
- Lynparza oral tablet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

OLARATUMAB

Products Affected

- Lartruvo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.

OMACETAXINE

Products Affected

- Synribo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INDUCTION: 3 MONTHS. POST INDUCTION OR RENEWAL: 3 TO 12 MONTHS
Other Criteria	CML INDUCTION THERAPY: TRIAL OF OR CONTRAINDICATION TO AT LEAST TWO OF THE FOLLOWING AGENTS: GLEEVEC, SPRYCEL, TASIGNA, BOSULIF OR ICLUSIG. APPROVAL FOR POST-INDUCTION THERAPY DURATION WILL DEPEND ON THE PATIENT'S HEMATOLOGIC RESPONSE, DEFINED AS AN ABSOLUTE NEUTROPHIL COUNT (ANC) GREATER THAN OR EQUAL TO $1.5 \times 10^9/L$, PLATELETS GREATER THAN OR EQUAL TO $100 \times 10^9/L$ WITHOUT BLOOD BLASTS OR THE PATIENT HAS BONE MARROW BLASTS AT LESS THAN 5 PERCENT. APPROVAL IS FOR 12 MONTHS IF HEMATOLOGIC RESPONSE IS MET. IF NOT MET, APPROVAL IS FOR 3 MONTHS.

OMALIZUMAB

Products Affected

- Xolair

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL CRITERIA FOR ASTHMA: PATIENT MEETS THE CRITERIA OF MODERATE TO SEVERE ASTHMA, POSITIVE SKIN PRICK OR RAST TEST, FEV1 LESS THAN 80%, DEMONSTRATED INADEQUATELY CONTROLLED SYMPTOMS ON INHALED CORTICOSTEROIDS AND SECOND ASTHMA CONTROLLER, BASELINE IGE SERUM LEVEL GREATER THAN OR EQUAL TO 30IU/ML. RENEWAL CRITERIA FOR ASTHMA: PHYSICIAN ATTESTATION OF IMPROVEMENT IN ASTHMA EXCERBATIONS FROM BASELINE AND A REDUCTION IN ORAL OR INHALED CORTICOSTEROID USE.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A SPECIALIST IN ALLERGY, PULMONARY MEDICINE, DERMATOLOGY OR IMMUNOLOGY.
Coverage Duration	ASTHMA: 12 MONTHS. CHRONIC IDIOPATHIC URTICARIA: 6 MONTHS.
Other Criteria	FOR CHRONIC IDIOPATHIC URTICARIA: PREVIOUS TRIAL OF OR CONTRAINDICATION TO A HIGH DOSE H1 ANTI-HISTAMINE (SUCH AS CLARINEX OR XYZAL) FOR AT LEAST 2 WEEKS AND STILL EXPERIENCE HIVES ON MOST DAYS OF THE WEEK.

OMBITASVIR-PARITAPREVIR-RITONAVIR

Products Affected

- Technivie

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	CIRRHOSIS, MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD-PUGH B OR C).
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. MUST BE USED CONCURRENTLY WITH RIBAVIRIN UNLESS PATIENT IS TREATMENT NAIVE AND HAS CONTRAINDICATION TO RIBAVIRIN. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER): ALFUZOSIN, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, RIFAMPIN, ERGOTAMINE, DIHYDROERGOTAMINE, ERGONOVINE, METHYLERGONOVINE, ETHINYL ESTRADIOL CONTAINING MEDICATIONS (SUCH AS COMBINED ORAL CONTRACEPTIVES, NUVARING, ORTHO EVRA OR XULANE TRANSDERMAL PATCH SYSTEM), LOVASTATIN, SIMVASTATIN, PIMOZIDE, EFAVIRENZ (ATRIPLA, SUSTIVA), REVATIO (SILDENAFIL DOSE OF 20MG AND/OR DOSED THREE TIMES DAILY FOR PAH), TRIAZOLAM, ORAL MIDAZOLAM, LOPINAVIR/RITONAVIR, RILPIVIRINE, SALMETEROL.</p>

OMBITASVIR-PARITAPREVIR-RITONAVIR-DASABUVIR

Products Affected

- Viekira Pak
- Viekira XR

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	DECOMPENSATED CIRRHOSIS, MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD-PUGH B OR C).
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: ALFUZOSIN, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, GEMFIBROZIL, RIFAMPIN, ERGOTAMINE, DIHYDROERGOTAMINE, ERGONOVINE, METHYLERGONOVINE, ETHINYL ESTRADIOL CONTAINING MEDICATIONS (SUCH AS COMBINED ORAL CONTRACEPTIVES, NUVARING, ORTHO EVRA OR XULANE TRANSDERMAL PATCH SYSTEM), ST. JOHN'S WORT, LOVASTATIN, SIMVASTATIN, PIMOZIDE, EFAVIRENZ, REVATIO, TRIAZOLAM, ORAL MIDAZOLAM, DARUNAVIR/RITONAVIR, LOPINAVIR/RITONAVIR, RILPIVIRINE, SALMETEROL.</p>

OPIOID DEPENDENCY AGENTS

Products Affected

- buprenorphine HCl sublingual

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	BUPRENORPHINE: 2 DAYS UNLESS PREGNANT (12 MO.) OR SERIOUS NALOXONE ALLERGY (12 MO.).
Other Criteria	BUPRENORPHINE MONOTHERAPY WILL BE APPROVED FOR THE FOLLOWING PATIENTS: PREGNANCY OR DOCUMENTATION OF SERIOUS NALOXONE ALLERGY DEFINED AS NALOXONE-INDUCED ANAPHYLAXIS, BRONCHOSPASM, OR ANGIONEUROTIC EDEMA, AND FOR PATIENTS BEING TRANSITIONED DIRECTLY FROM A LONG ACTING OPIOID (I.E. METHADONE, FENTANYL PATCH, OR OTHER ER OPIOIDS). FOR PATIENTS BEING TRANSITIONED DIRECTLY FROM A LONG-ACTING OPIOID APPROVAL FOR BUPRENORPHINE MONOTHERAPY WILL BE LIMITED TO USE DURING INDUCTION THERAPY ONLY (2 DAYS). FOR NEW STARTS: ADDITIONAL CONSIDERATION WILL BE PROVIDED FOR A QUANTITY EXCEPTION FOR INDUCTION DOSING FOR 2 DAYS OF THERAPY.

OSIMERTINIB MESYLATE

Products Affected

- Tagrisso

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

OXYMETHOLONE

Products Affected

- Anadrol-50

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, WOMEN WHO ARE OR MAY BECOME PREGNANT, NEPHROSIS OR THE NEPHROTIC PHASE OF NEPHRITIS, HYPERSENSITIVITY TO THE DRUG AND SEVERE HEPATIC DYSFUNCTION.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PALBOCICLIB

Products Affected

- Ibrance

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PALIVIZUMAB

Products Affected

- Synagis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	GESTASTIONAL AGE
Age Restrictions	LESS THAN 24 MONTHS OF AGE.
Prescriber Restrictions	
Coverage Duration	1 MONTH TO 5 MONTHS . SEE OTHER CRITERIA FOR MORE INFORMATION.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT RECOMMENDATIONS FROM THE AMERICAN ACADEMY OF PEDIATRICS FOR PALIVIZUMAB PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS INFECTIONS. INITIAL: APPROVAL WILL BE FOR AT LEAST 1 MONTH AND NO GREATER THAN 5 MONTHS DEPENDENT UPON REMAINING LENGTH OF RESPIRATORY SYNCYTIAL VIRUS (RSV) SEASON. RENEWAL: ADDITIONAL 1 MONTH OF TREATMENT FOR CARDIOPULMONARY BYPASS SURGERY DURING RSV PROPHYLAXIS SEASON.

PANOBINOSTAT

Products Affected

- Farydak

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PARATHYROID HORMONE

Products Affected

- Natpara

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PAZOPANIB

Products Affected

- Votrient

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION

Products Affected

- Adcirca
- sildenafil (antihypertensive) oral

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	PATIENT CANNOT CONCURRENTLY OR INTERMITTENTLY BE TAKING ORAL ERECTILE DYSFUNCTION AGENTS (CIALIS, VIAGRA), ANY ORGANIC NITRATES IN ANY FORM, OR GUANYLATE CYCLASE (GC) STIMULATORS (ADEMPAS).
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. REQUEST FOR ADCIRCA REQUIRE TRIAL OR CONTRAINDICATION TO REVATIO. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION - IV

Products Affected

- sildenafil (antihypertensive) intravenous

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	PATIENT CANNOT CONCURRENTLY OR INTERMITTENTLY BE TAKING ORAL ERECTILE DYSFUNCTION AGENTS (CIALIS, VIAGRA), ANY ORGANIC NITRATES IN ANY FORM, OR GUANYLATE CYCLASE (GC) STIMULATORS (ADEMPAS).
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. REQUEST FOR ADCIRCA REQUIRE TRIAL OR CONTRAINDICATION TO REVATIO. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

PEDIATRIC VITAMINS

Products Affected

- POLY-VITA WITH IRON DROPS
- POLYVITAMIN W-IRON DROPS
- TRI-VI-SOL DROPS
- TRI-VITA DROPS
- TRI-VITAMIN DROPS

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	REIMBURSABLE FOR CHILDREN UP TO THE 5TH BIRTHDAY ONLY.

PEG-INTERFERON ALFA-2B-SYLATRON

Products Affected

- Sylatron

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	OVERALL DURATION OF THERAPY LIMITED TO 5 YEARS.

PEMBROLIZUMAB

Products Affected

- Keytruda

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT REQUESTS FOR YERVOY, TAFINLAR, OR ZELBORAF

PIMAVANSERIN

Products Affected

- Nuplazid

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OR OLDER
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (SUCH AS A PSYCHIATRIST).
Coverage Duration	INITIAL 12 MONTHS. RENEWAL 12 MONTHS.
Other Criteria	RENEWAL REQUIRES THAT THE PATIENT HAS EXPERIENCED AN IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.

PIRFENIDONE

Products Affected

- Esbriet oral capsule
- Esbriet oral tablet 267 mg, 801 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	NOT APPROVED FOR PATIENTS WITH KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, AND CANCER). NOT APPROVED IF THE PATIENT HAS NOT OBTAINED LIVER FUNCTION TESTS.
Required Medical Information	PATIENT WITH USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	PATIENT HAS A PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50%.

POMALIDOMIDE

Products Affected

- Pomalyst

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PONATINIB

Products Affected

- Iclusig oral tablet 15 mg, 45 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PRAMLINTIDE

Products Affected

- SymlinPen 120
- SymlinPen 60

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	TYPE I OR TYPE II DIABETES: REQUIRING INSULIN OR CONTINUOUS INSULIN INFUSION (INSULIN PUMP) FOR GLYCEMIC CONTROL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

PRENATAL OTC VITAMINS

Products Affected

- CVS PRENATAL GUMMY VITAMINS
- CVS PRENATAL VITAMIN TABLET
- CVS WOMEN'S PRENATAL + DHA
- DAILY PRENATAL COMBO PACK
- EQL PRENATAL VITAMIN TABLET
- EXPECTA PRENATAL COMBO PACK
- GS PRENATAL VITAMINS TABLET
- KPN TABLET
- ONE A DAY PRENATAL DHA PACK
30 LIQ GELS,30 TABS
- ONE-A-DAY PRENATAL 1 DHA
SFGL
- PERRY PRENATAL CAPSULE
- PRENATAL + DHA COMBO PACK
- PRENATAL 19 CHEWABLE TABLET
(OTC)
- PRENATAL DHA+COMPLETE
PRENATAL
- PRENATAL FORMULA TABLET
- PRENATAL GUMMIES
- PRENATAL MULTI + DHA SOFTGEL
P/F, GLUTEN-FREE
- PRENATAL MULTI-DHA SOFTGEL
- PRENATAL MULTIVITAMIN
TABLET
- PRENATAL MULTIVITAMIN-DHA
SFGL
- PRENATAL ONE TABLET
- PRENATAL TABLET
- PRENATAL TABLET (OTC)
- PRENATAL TABLET OUTER (OTC)
- PRENATAL VITAMIN TABLET
- PRENATAL VITAMINS TABLET
PHOSPHORUS FREE
- PRENATAL-1 CAPSULE
- PROFE FORTE CAPSULE
- PV PRENATAL FORMULA TABLET
- RA ONE DAILY PRENATAL DHA
PACK 30'S TAB & 30'S CAP
- RA PRENATAL TABLET
- RIGHT STEP PRENATAL VIT TAB
- SIMILAC PRENATAL COMBO PACK
- SM ONE DAILY PRENATAL COMBO
PK
- SM PRENATAL VITAMINS TABLET
- STUART ONE CAPSULE
- THERANATAL CORE NUTRITION
TAB
- THERANATAL OVAVITE COMBO
PACK
- THERANATAL PLUS COMBO PACK
- VINACAL B PRENATAL COMBO
PACK

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A

PA Criteria	Criteria Details
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO USE BY EXPECTANT FEMALES WITH CONFIRMED POSITIVE PREGNANCY TEST CONDUCTED BY HER PHYSICIAN.

PYRIMETHAMINE

Products Affected

- Daraprim

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D, ADDITIONAL CONSIDERATION FOR CHRONIC MAINTENANCE THERAPY FOR TOXOPLASMOSIS AND TOXOPLASMOSIS PROPHYLAXIS.
Exclusion Criteria	
Required Medical Information	MALARIA: PLASMODIA SUSCEPTIBLE TESTING. TOXOPLASMOSIS:CD4 LEVEL
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE MALARIA AND CHEMOPROPHYLAXIS: INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS. SEE OTHER CRITERIA FIELD

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: ACUTE MALARIA TREATMENT AND MALARIA CHEMOPROPHYLAXIS REQUIRES THAT THE PATIENT HAS MALARIA SUSCEPTIBLE TO PYRIMETHAMINE AND A PREVIOUS TRIAL OF PLAQUENIL (HYDROXYCHLOROQUINE SULFATE) AND MALARONE (ATOVAQUONE/PROGUANIL) (UNLESS THESE REGIMENS ARE RESISTANT IN THE SPECIFIC REGION AS INDICATED BY REGIONAL PLASMODIA SUSCEPTIBILITY). PRIMARY PROPHYLAXIS OF TOXOPLASMOSIS IN PATIENTS WITH HIV REQUIRES PREVIOUS TRIAL OF OR CONTRAINDICATION TO BACTRIM (SMX/TMP). RENEWAL: CONTINUATION OF TREATMENT FOLLOWING ACUTE MALARIA REQUIRES PREVIOUS INFECTION WITH MALARIA SUSCEPTIBLE TO PYRIMETHAMINE WITH SUBSEQUENT CLINICAL CURE (ELIMINATION OF MALARIA SYMPTOMS DEFINED AS CHILLS, FEVER, SWEATS, GENERAL MALAISE) FOLLOWED BY SYMPTOMS OF RELAPSE. CONTINUATION OF MALARIA CHEMOPROPHYLAXIS REQUIRES THE PATIENT WILL BE TRAVELING TO OR RESIDING IN AN AREA WHERE PLASMODIA SUSCEPTIBLE TO PYRIMETHAMINE EXISTS (MALARIA MUST BE SENSITIVE TO PYRIMETHAMINE).CONTINUED TREATMENT OF TOXOPLASMOSIS REQUIRES ONE OF THE FOLLOWING: 1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING) OR 2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENT ANTI-RETROVIRAL THERAPY IF HIV POSITIVE. CONTINUATION OF PRIMARY PROPHYLAXIS FOR TOXOPLASMOSIS WITH HIV REQUIRES CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENT ANTI RETROVIRAL THERAPY. TOXOPLASMOSIS: INITIAL: 8 WEEKS. RENEWAL: 6 MONTHS. PRIMARY PROPHYLAXIS OF TOXOPLASMOSIS: INITIAL AND RENEWAL IS 12 MONTHS.</p>

QUININE SULFATE

Products Affected

- quinine sulfate

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

RAMUCIRUMAB

Products Affected

- Cynamza

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

REGORAFENIB

Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOR COLORECTAL CANCER: TRIAL OF OR CONTRAINDICATION TO AN ANTI-VEGF THERAPY SUCH AS AVASTIN OR ZALTRAP AND A FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY SUCH AS FOLFOX, FOLFOXIRI, FOLFIRI, CAPEOX, INFUSIONAL 5-FU/LV OR CAPECITABINE. IF APPLICABLE, A TRIAL OF OR CONTRAINDICATION TO AN ANTI-EGFR THERAPY SUCH AS ERBITUX OR VECTIBIX IS ALSO REQUIRED FOR KRAS WILD TYPE COLORECTAL CANCER. FOR GIST, A TRIAL OF OR CONTRAINDICATION TO GLEEVEC AND SUTENT IS REQUIRED.

RESLIZUMAB

Products Affected

- Cinqair

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	CONCURRENT USE OF XOLAIR
Required Medical Information	BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 400 CELLS/MCL WITHIN THE LAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY MEDICINE
Coverage Duration	INITIAL 24 WEEKS. RENEWAL 12 MONTHS
Other Criteria	INITIAL THERAPY: PATIENT CURRENTLY TREATED WITH A MAXIMALLY TOLERATED DOSE OF INHALED CORTICOSTEROIDS. RENEWAL REQUIRES DOCUMENTATION THAT THE PATIENT HAS EXPERIENCED AT LEAST A 25 PERCENT REDUCTION IN ASTHMA EXACERBATIONS (FOR EXAMPLE: HOSPITALIZATIONS, URGENT OR EMERGENT CARE VISITS, USE OF RESCUE MEDICATIONS, ETC.) FROM BASELINE.

RIBOCICLIB

Products Affected

- Kisqali mg/day(200 mg x 2)-2.5 mg, 600
- Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 3)-2.5 mg
mg/day(200 mg x 1)-2.5 mg, 400

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

RIFAXIMIN

Products Affected

- Xifaxan oral tablet 200 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS' DIARRHEA: 1 FILL IN 1 MONTH.
Other Criteria	

RIFAXIMIN-HEPATIC ENCEPHALOPATHY

Products Affected

- Xifaxan oral tablet 550 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	HEPATIC ENCEPHALOPATHY: 12 MO IRRITABLE BOWEL SYNDROME WITH DIARRHEA: INITIAL: 12 WKS. RENEWAL:12 MO
Other Criteria	INITIAL: HEPATIC ENCEPHALOPATHY (HE): TRIAL OF LACTULOSE OR CONCURRENT LACTULOSE THERAPY. IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D): TRIAL WITH DICYCLOMINE (UNLESS CONTRAINDICATED) RENEWAL: ISB-D: ALL OF THE FOLLOWING CRITERIA MUST HAVE BEEN MET: AT LEAST 10 WEEKS HAVE PASSED SINCE THE LAST TREATMENT COURSE OF RIFAXIMIN, AND PATIENT HAS EXPERIENCED AT LEAST 30% DECREASE IN ABDOMINAL PAIN (ON A 0-10 POINT PAIN SCALE), AND PATIENT HAS EXPERIENCED AT LEAST 50% REDUCTION IN THE NUMBER OF DAYS PER WEEK WITH A STOOL CONSISTENCY OF MUSHY STOOL (BRISTOL STOOL SCALE TYPE 6) OR ENTIRELY LIQUID STOOL (BRISTOL STOOL SCALE TYPE 7).

RIOCIGUAT

Products Affected

- Adempas

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	INITIAL FOR PAH: PATIENT IS NOT CONCURRENTLY TAKING NITRATES OR NITRIC OXIDE DONORS (E.G. AMYL NITRATE), PHOSPHODIESTERASE INHIBITORS (E.G. SILDENAFIL, TADALAFIL, OR VARDENAFIL), OR NON-SPECIFIC PDE INHIBITORS (E.G. DIPYRIDAMOLE, THEOPHYLLINE). INITIAL FOR CTEPH: PATIENT IS NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH. PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. PATIENT IS NOT CONCURRENTLY OR INTERMITTENTLY TAKING NITRATES, NITRIC OXIDE DONORS OR ANY PDE INHIBITORS (E.G. VIAGRA, CIALIS, DIPYRAMIDOLE).
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. DIAGNOSIS OF PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) WHO GROUP 4. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL FOR PAH: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. PREVIOUS TRIAL OF OR CONTRAINDICATION TO A PHOSPHODIESTERASE-5 (PDE-5) INHIBITOR, SUCH AS REVATIO OR ADCIRCA.</p> <p>RENEWAL FOR PAH AND CTEPH: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.</p>

RITUXIMAB

Products Affected

- Rituxan

PA Criteria	Criteria Details
Covered Uses	ALL FDA ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NHL, CLL: ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO. RENEWAL: 12 MONTHS. NHL: 1 YEAR. CLL: 6 MO. WG, MPA: 3 MONTH.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS: PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA OR ACTEMRA.

RITUXIMAB SQ

Products Affected

- Rituxan Hycela

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THE PATIENT HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE.

RUCAPARIB

Products Affected

- Rubraca

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

RUXOLITINIB

Products Affected

- Jakafi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: IMPROVEMENT OR MAINTENANCE OF SYMPTOM IMPROVEMENT SUCH AS A 50% OR GREATER REDUCTION IN TOTAL SYMPTOM SCORE ON THE MODIFIED MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 OR 50% OR GREATER REDUCTION IN PALPABLE SPLEEN LENGTH, OR REDUCTION OF 35% OR GREATER FROM BASELINE SPLEEN VOLUME AFTER 6 MONTHS OF THERAPY.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	

SAFINAMIDE MESYLATE

Products Affected

- Xadago

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

SARILUMAB

Products Affected

- Kevzara

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ACTEMRA, CIMZIA, ORENCIA, OR XELJANZ.

SEBELIPASE ALFA

Products Affected

- Kanuma

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	BLOOD TEST OR DRIED BLOOD SPOT TEST INDICATING LOW OR ABSENT LYSOSOMAL ACID LIPASE DEFICIENCY (LAL) ENZYME ACTIVITY, OR A GENETIC TEST INDICATING THE PRESENCE OF ALTERED LIPA GENE(S)
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, HEPATOLOGIST, GASTROENTEROLOGIST, MEDICAL GENETICIST, LIPIDOLOGIST, OR A METABOLIC SPECIALIST.
Coverage Duration	LAL INITIAL 6 OR 12 MONTHS, SEE OTHER CRITERIA. RENEWAL: 12 MONTHS.

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY, AS CONFIRMED BY THE PRESENCE OF CLINICAL FEATURES (E.G., HEPATOMEGALY, ELEVATED SERUM TRANSAMINASES, DYSLIPIDEMIA, SPLENOMEGALY) PLUS ANY OF THE FOLLOWING: A BLOOD TEST INDICATING LOW OR ABSENT LEVELS OF LAL ENZYME ACTIVITY, A DRIED BLOOD SPOT TEST INDICATING LOW OR ABSENT LAL ENZYME ACTIVITY, OR A GENETIC TEST INDICATING THE BI-ALLELIC PRESENCE OF ALTERED LIPA GENE(S).</p> <p>RENEWAL:DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING AFTER THE FIRST 6 MONTHS OF LIFE AND NOT CONSIDERED RAPIDLY PROGRESSIVE REQUIRES DOCUMENTED IMPROVEMENT IN ANY ONE OF THE FOLLOWING CLINICAL PARAMETERS ASSOCIATED WITH LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY DURING THE PAST 6 MONTHS: A RELATIVE REDUCTION FROM BASELINE IN ANY ONE OF THE FOLLOWING LIPID LEVELS (LDL-C, NON-HDL-C, OR TRIGLYCERIDES), NORMALIZATION OF ASPARTATE AMINOTRANSFERASE (AST) BASED ON AGE- AND GENDER-SPECIFIC NORMAL RANGES, A DECREASE IN LIVER FAT CONTENT COMPARED TO BASELINE ASSESSED BY ABDOMINAL IMAGING (E.G., MULTI-ECHO GRADIENT ECHO [MEGE] MRI). DIAGNOSIS OF RAPIDLY PROGRESSIVE LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING WITHIN THE FIRST 6 MONTHS OF LIFE:12 MONTHS. A DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING AFTER THE FIRST 6 MONTHS OF LIFE AND NOT CONSIDERED RAPIDLY PROGRESSIVE: INITIAL: 6 MONTHS</p>

SECUKINUMAB

Products Affected

- Cosentyx
- COSENTYX (150 MG/ML) 300 MG DOSE-2 PENS
- COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES
- Cosentyx Pen

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	PLAQUE PSORIASIS (PSO): MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% SURFACE AREA OR PSORIATIC LESIONS AFFECT THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PLAQUE PSORIASIS (PSO): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST
Coverage Duration	INITIAL: 4 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES
Other Criteria	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA AND ONE CONVENTIONAL THERAPY SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL WITH HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL WITH HUMIRA

SELEXIPAG

Products Affected

- Upravi oral tablet 1,000 mcg, 1,200 mcg, 1,400 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg
- Upravi oral tablets, dose pack

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS

SILTUXIMAB

Products Affected

- Sylvant

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

SIMEPREVIR

Products Affected

- Olysio

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDS A GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS. FOR ALL GENOTYPE 1A: NS3 80K POLYMORPHISM LAB TEST AT BASELINE.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (FOR EXAMPLE HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDS A GUIDANCE.

PA Criteria	Criteria Details
Other Criteria	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. PATIENT MUST NOT BE TAKING ANY OF THE FOLLOWING INTERACTING MEDICATIONS: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ERYTHROMYCIN (DOES NOT INCLUDE TOPICAL FORMULATIONS), CLARITHROMYCIN, TELITHROMYCIN, ITRACONAZOLE, KETOCONAZOLE, POSACONAZOLE, FLUCONAZOLE (DOES NOT INCLUDE TOPICAL FORMULATIONS), VORICONAZOLE, DEXAMETHASONE, CISAPRIDE, CYCLOSPORINE, ROSUVASTATIN DOSE ABOVE 10MG, ATORVASTATIN DOSE ABOVE 40MG, OR ANY OF THE FOLLOWING HIV MEDICATIONS: COBICISTAT-CONTAINING MEDS (E.G., STRIBILD), ANY HIV PROTEASE INHIBITOR (ATAZANAVIR, FOSAMPRENAVIR, LOPINAVIR, INDINAVIR, NELFINAVIR, SAQUINAVIR, OR TIPRANAVIR) RITONAVIR, DARUNAVIR/RITONAVIR, DELAVIRIDINE, ETRAVIRINE, NEVIRAPINE, EFAVIRENZ). PATIENT MUST ALSO NOT BE TAKING AMIODARONE IF ON COMBINATION REGIMEN OF SOVALDI AND OLYSIO.</p>

SOFOSBUVIR

Products Affected

- Sovaldi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSa GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS. FOR ALL GENOTYPE 1 PATIENTS USING OLYSIO AND SOVALDI AND HAVE GENOTYPE 1A: NS3 80K POLYMORPHISM LAB TEST AT BASELINE.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATIONS WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSa GUIDANCE.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSa GUIDANCE. FOR PATIENTS ON SOVALDI PLUS DAKLINZA REGIMENS THERE WILL BE NO APPROVALS FOR CONCURRENT USE OF ANY OF THESE (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER) MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, OR RIFAMPIN. REQUESTS FOR SOVALDI IN COMBINATION WITH DAKLINZA OR OLYSIO WILL REQUIRE THAT THE PATIENT ALSO MEETS ALL CRITERIA FOR THE RESPECTIVE AGENT USED (DAKLINZA OR OLYSIO).

SOFOSBUVIR/VELPATASVIR

Products Affected

- Epclusa

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDS A GUIDANCE
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL
Age Restrictions	18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDS A GUIDANCE.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDS A GUIDANCE. HCV RNA LEVEL WITHIN PAST 6 MONTHS. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED BY THE MANUFACTURER: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANAVIR/RITONAVIR OR TOPOTECAN. PATIENT MUST NOT HAVE SEVERE RENAL IMPAIRMENT, ESRD OR ON HEMODIALYSIS. RIBAVIRIN USE REQUIRED FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS.

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Products Affected

- Vosevi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.
Exclusion Criteria	SEVERE RENAL IMPAIRMENT, ESRD OR ON HEMODIALYSIS. MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. HCV RNA LEVEL WITHIN PAST 6 MONTHS. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED BY THE MANUFACTURER: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR OR TIPRANAVIR/RITONAVIR.

SOMATROPIN - GROWTH HORMONE

Products Affected

- Humatrope
- Omnitrope
- Saizen
- Saizen click.easy
- Zomacton

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE WITH CLOSED EPIPHYSES.
Required Medical Information	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH: ENDOCRINOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	INITIAL: PREVIOUS TRIAL OF PREFERRED FORMULARY ALTERNATIVES NORDITROPIN AND GENOTROPIN PER FDA INDICATION. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.

SOMATROPIN - SEROSTIM

Products Affected

- Serostim subcutaneous recon soln 4 mg, 5 mg, 6 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
Required Medical Information	HIV/WASTING: MEETS CRITERIA OF WEIGHT LOSS: 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, OR 7.5 % OVER 6 MONTHS, OR 5PERCENT BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, OR A BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND A BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, OR BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND A BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, OR BMI LESS THAN 20 KG PER METER SQUARED.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST (SBS), OR INFECTIOUS DISEASE SPECIALIST
Coverage Duration	3 MONTHS
Other Criteria	HIV/WASTING: CURRENTLY ON ANTIRETROVIRAL THERAPY. IF CURRENTLY ON GROWTH HORMONE, PATIENT HAS SHOWN CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT OR IF NOT ON GROWTH HORMONE, PATIENT HAS HAD INADEQUATE RESPONSE TO PREVIOUS THERAPY. (I.E. EXERCISE TRAINING, NUTRITIONAL SUPPLEMENTS, APPETITE STIMULANTS, OR ANABOLIC STEROIDS).

SOMATROPIN - ZORBTIVE

Products Affected

- Zorbtive

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST
Coverage Duration	SHORT BOWEL: 4 WEEKS ONCE
Other Criteria	

SOMATROPIN-NORDITROPIN AND GENOTROPIN

Products Affected

- Genotropin
- Genotropin MiniQuick
- Norditropin FlexPro

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE WITH CLOSED EPIPHYSES.
Required Medical Information	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH: ENDOCRINOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT (I.E. INCREASED HEIGHT OR INCREASED GROWTH VELOCITY).

SOMATROPIN-NUTROPIN AND NUTROPIN AQ

Products Affected

- Nutropin AQ
- Nutropin AQ Nuspin

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE DUE TO CKD IF PATIENT HAS HAD A RENAL TRANSPLANT, OR GROWTH FAILURE WITH CLOSED EPIPHYSES.
Required Medical Information	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH: ENDOCRINOLOGIST. FOR GROWTH HORMONE FAILURE DUE TO CRI: NEPHROLOGIST.
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	ALL DIAGNOSES EXCEPT FOR CHRONIC KIDNEY DISEASE (CKD): INITIAL: PREVIOUS TRIAL OF PREFERRED FORMULARY ALTERNATIVES NORDITROPIN AND GENOTROPIN PER FDA INDICATION. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT (I.E. INCREASED HEIGHT OR INCREASED GROWTH VELOCITY). FOR GROWTH FAILURE SECONDARY TO CKD: PATIENT HAS NOT RECEIVED A RENAL TRANSPLANT.

SONIDEGIB

Products Affected

- Odomzo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

SORAFENIB TOSYLATE

Products Affected

- Nexavar

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

SUNITINIB MALATE

Products Affected

- Sutent

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO GLEEVEC.

TALIMOGENE

Products Affected

- Imlygic injection suspension 10exp6 (1 million) PFU/mL, 10exp8 (100 million) PFU/mL

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	HISTORY OF PRIMARY OR ACQUIRED IMMUNODEFICIENT STATES, LEUKEMIA, LYMPHOMA, OR AIDS. PATIENT IS NOT CURRENTLY RECEIVING IMMUNOSUPPRESSIVE THERAPY.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	IMLYGIC TO BE INJECTED INTO CUTANEOUS, SUBCUTANEOUS, AND OR NODAL LESIONS THAT ARE VISIBLE, PALPABLE, OR DETECTABLE BY ULTRASOUND GUIDANCE. NO CONCURRENT USE WITH PEMBROLIZUMAB, NIVOLUMAB, IPILIMUMAB, DABRAFENIB, TRAMETINIB, VEMURAFENIB, INTERLEUKIN-2, INTERFERON, DACARBAZINE, TEMOZOLOMIDE, PACLITAXEL, CARBOPLATIN, IMATINIB, MELPHALAN, IMIQUIMOD, OR RADIATION THERAPY.

TASIMELTEON

Products Affected

- Hetlioz

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TEDUGLUTIDE

Products Affected

- GATTEX 5 MG 30-VIAL KIT
- Gattex One-Vial

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OF AGE AND OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PATIENT IS DEPENDENT ON INTRAVENOUS PARENTERAL NUTRITION DEFINED AS REQUIRING PARENTERAL NUTRITION AT LEAST THREE TIMES PER WEEK.

TELOTRISTAT

Products Affected

- Xermelo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TEMOZOLOMIDE

Products Affected

- Temodar intravenous

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TERIFLUNOMIDE

Products Affected

- Aubagio

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TERIPARATIDE

Products Affected

- Forteo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	GREATER THAN 24 MONTHS OF THERAPY.
Required Medical Information	A PATIENT WITH EITHER A DIAGNOSIS OF SEVERE OSTEOPOROSIS (T-SCORE LESS THAN -2.5 WITH FRAGILITY FRACTURE) OR A T SCORE EQUAL TO OR LESS THAN -2.5 AND MULTIPLE RISK FACTORS FOR FRACTURE (E.G. HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS), OR FAILED AN ADEQUATE TRIAL OF BISPHOSPHONATES, IS INTOLERANT, OR HAS A CONTRAINDICATION TO BISPHOSPHONATES.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TESTOSTERONE

Products Affected

- Androderm
- AndroGel transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)
- AndroGel transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)
- testosterone cypionate
- testosterone enanthate
- testosterone transdermal gel
- testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)
- testosterone transdermal gel in packet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL CONSIDERATION FOR GENDER DYSPHORIA.
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM CONFIRMED BY EITHER: 1) LAB CONFIRMED TOTAL SERUM TESTOSTERONE LEVEL OF LESS THAN 300 NG/DL OR 2) A LOW TOTAL SERUM TESTOSTERONE LEVEL AS INDICATED BY A LAB RESULT WITH A REFERENCE RANGE OBTAINED WITHIN 90 DAYS, OR 3) A FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 PG/ML.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	LIFETIME OF MEMBERSHIP IN PLAN
Other Criteria	

TETRABENAZINE

Products Affected

- tetrabenazine

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	NEUROLOGIST
Coverage Duration	12 MONTHS
Other Criteria	

THALIDOMIDE

Products Affected

- Thalomid

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TOCILIZUMAB IV

Products Affected

- Actemra

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL FOR RA, PJIA, OR SJIA: PHYSICIAN ATTESTATION OF IMPROVEMENT
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS (RA)/POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST
Coverage Duration	INITIAL: RA: 7 MOS. PJIA: 5 MOS. SJIA: 12 MOS. CRS: 1 MO. RENEWAL: 12 MOS FOR RA, PJIA, OR SJIA
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PREVIOUS TRIAL WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. NOT APPROVED FOR PATIENTS ON CONCURRENT THERAPY WITH KINERET (ANAKINRA), ORENCIA (ABATACEPT), OR ANOTHER TNF (TUMOR NECROSIS FACTOR) INHIBITOR: HUMIRA, ENBREL, CIMZIA, REMICADE, SIMPONI, OR SIMPONI ARIA.

TOCILIZUMAB SQ

Products Affected

- Actemra

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 7 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. NOT APPROVED FOR PATIENTS ON CONCURRENT THERAPY WITH KINERET (ANAKINRA), ORENCIA (ABATACEPT) OR ANOTHER TNF (TUMOR NECROSIS FACTOR) INHIBITOR: HUMIRA, ENBREL, CIMZIA, REMICADE, SIMPONI OR SIMPONI ARIA.

TOFACITINIB

Products Affected

- Xeljanz
- Xeljanz XR

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	RA: INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS: PREVIOUS TRIAL WITH HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

TOPICAL TRETINOIN

Products Affected

- tretinoin
- TRETINOIN GEL MICRO 0.04% TUBE
- TRETINOIN GEL MICRO 0.1% TUBE
- tretinoin microspheres topical gel with pump

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	WRINKLES, PHOTOAGING, MELASMA.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TRABECTEDIN

Products Affected

- Yondelis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TRAMETINIB DIMETHYL SULFOXIDE

Products Affected

- Mekinist oral tablet 0.5 mg, 2 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

TRASTUZUMAB

Products Affected

- Herceptin

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	BREAST CANCER, METASTATIC BREAST CANCER, GASTRIC CANCER: HER2 POSITIVE
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	B VS D COVERAGE CONSIDERATION.

TREPROSTINIL DIOLAMINE

Products Affected

- Orenitram

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. PATIENT DOES NOT HAVE SEVERE HEPATIC IMPAIRMENT. PREVIOUS TREATMENT WITH UPTRAVI AND PREVIOUS OR CURRENT TREATMENT WITH ONE OF THE FOLLOWING: A PHOSPHODIESTERASE-5 INHIBITOR (E.G., REVATIO [SILDENAFIL] OR ADCIRCA [TADALAFIL]) OR AN ENDOTHELIN RECEPTOR ANTAGONIST (E.G., TRACLEER [BOSENTAN], LETAIRIS [AMBRISENTAN]), OR OPSUMIT [MACITENTAN]). TRIAL OF 2 FORMULARY AGENTS (UPTRAVI AND A PHOSPHODIESTERASE-5 INHIBITOR OR ENDOTHELIN RECEPTOR ANTAGONIST) IS NOT REQUIRED IF THE PATIENT WAS PREVIOUSLY STABLE ON ORENITRAM. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.</p>

TREPROSTINIL INHALED

Products Affected

- Tyvaso

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS III-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	THIS DRUG MAYBE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. NEBULIZER THERAPY IS COVERED UNDER PART B FOR PATIENTS WHO ARE USING THE MEDICATION VIA A NEBULIZER IN THEIR OWN HOME. THOSE WHO ARE NOT USING IT IN THEIR HOME WILL BE COVERED UNDER PART D. INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

TREPROSTINIL SODIUM INJECTABLE

Products Affected

- Remodulin

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	COVERED UNDER LOCAL COVERAGE POLICY OF APPLICABLE MEDICARE DMERC.
Required Medical Information	FORMULARY DRUG ADMINISTERED IN A LONG TERM CARE FACILITY TO A PATIENT WHOSE PART A COVERAGE HAS EXPIRED OR FORMULARY DRUG NOT ADMINISTERED VIA AN IMPLANTABLE PUMP OR AN EXTERNAL PUMP OR DRUG ADMINISTERED VIA AN IMPLANTABLE PUMP/AN EXTERNAL PUMP. DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. CONTINUATION OF CURRENT REMODULIN THERAPY: PATIENT MUST HAVE NYHA/WHO FC II-IV SYMPTOMS. NEW REQUESTS FOR REMODULIN THERAPY: PATIENT MUST HAVE NYHA/WHO FC III-IV SYMPTOMS. NEW REQUESTS FOR REMODULIN THERAPY FOR PATIENTS WITH NYHA/WHO FC II SYMPTOMS REQUIRES A TRIAL OF OR CONTRAINDICATION TO A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5) (E.G., REVATIO, ADCIRCA) OR AN ENDOTHELIN RECEPTOR ANTAGONIST (ERA) (E.G., LETAIRIS, OPSUMIT, TRACLEER). RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.</p>

TRIFLURIDINE/TIPIRACIL

Products Affected

- Lonsurf oral tablet 15-6.14 mg, 20-8.19 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

USTEKINUMAB

Products Affected

- Stelara subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL FOR PSORIATIC ARTHRITIS OR PLAQUE PSORIASIS: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: PSORIATIC ARTHRITIS: DERMATOLOGIST OR RHEUMATOLOGIST. PLAQUE PSORIASIS: DERMATOLOGIST. CROHN'S DISEASE: GASTROENTEROLOGIST.
Coverage Duration	INITIAL: PSA, PSO, CD: 4 MONTHS. CD WITH PREVIOUS DOSE IV: 2 MONTHS. RENEW ALL: 12 MO
Other Criteria	INITIAL: PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF OR CONTRAINDICATION TO PREFERRED TNF INHIBITORS: HUMIRA FOLLOWED BY CIMZIA.

USTEKINUMAB IV

Products Affected

- Stelara intravenous

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	2 MONTHS
Other Criteria	PREVIOUS TRIAL OF OR CONTRAINDICATION TO THE PREFERRED TNF INHIBITORS: HUMIRA FOLLOWED BY CIMZIA. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

VALBENZAZINE TOSYLATE

Products Affected

- Ingrezza oral capsule 40 mg, 80 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	N/A
Required Medical Information	PATIENT HAS BEEN USING ANTIPSYCHOTIC MEDICATIONS OR METOCLOPRAMIDE FOR AT LEAST 3 MONTHS (OR AT LEAST 1 MONTH IF PATIENT IS 60 YEARS OF AGE OR OLDER) PER PHYSICIAN ATTESTATION
Age Restrictions	N/A
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
Coverage Duration	12 MONTHS
Other Criteria	MODERATE TO SEVERE TARDIVE DYSKINESIA HAS BEEN PRESENT FOR AT LEAST 3 MONTHS

VANDETANIB

Products Affected

- Caprelsa oral tablet 100 mg, 300 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

VEMURAFENIB

Products Affected

- Zelboraf

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	BRAFV600E MUTATION
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

VENETOCLAX

Products Affected

- Venclexta oral tablet 10 mg, 100 mg, 50 mg
- Venclexta Starting Pack

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D
Exclusion Criteria	NONE
Required Medical Information	NONE
Age Restrictions	NONE
Prescriber Restrictions	NONE
Coverage Duration	12 MONTHS
Other Criteria	NONE

VISMODEGIB

Products Affected

- Erivedge

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

INDEX

12 HOUR RELIEF TABLET	16	ALER-CAPS 25 MG CAPSULE.....	19
1ST CHOICE THIN LANCETS.....	102	ALER-TAB 25 MG TABLET.....	19
1ST TIER COMFORTOUCH 28G LANCT	102	Aliqopa.....	52
1ST TIER COMFORTOUCH 30G LANCT	102	ALKA-SELTZER PLUS ALLERGY TAB.....	19
25DPH-7.5PEH LIQUID.....	16	ALLER-CHLOR 2 MG/5 ML SYRUP..	16
ACCU-CHEK FASTCLIX LANCETS	102	ALLER-CHLOR 4 MG TABLET	16
ACCU-CHEK MULTICLIX LANCETS.....	102	ALLERGY 4 MG TABLET.....	16
ACCU-CHEK SAFE-T-PRO 23G LANCT	102	ALLERHIST-1 1.34 MG TABLET.....	16
ACCU-CHEK SAFE-T-PRO PLUS 23G.....	102	Allzital.....	114
ACCU-CHEK SOFTCLIX LANCETS	102	ALTERNATE SITE 26G LANCETS RECAPABLE.....	102
ACETAMINOPHEN 160 MG/5 ML ELX.....	6	Alunbrig.....	40
Actemra.....	242, 243	AMBI 60PSE-4CPM TABLET	16
ACTI-LANCE LITE 28G LANCETS..	102	Ampyra.....	58
ACTI-LANCE SPECIAL 17G LANCETS.....	102	Anadrol-50.....	179
ACTI-LANCE UNIVERS 23G LANCETS.....	102	Androderm.....	239
Adcetris.....	39	AndroGel transdermal gel in metered- dose pump 20.25 mg/1.25 gram (1.62 %)	239
Adcirca.....	185	AndroGel transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram).....	239
Adempas.....	206	ANTI HISTAMINE 25 MG CAPSULE..	19
ADVANCED TRAVEL 28G LANCETS 28G,SINGLE-USE,STRL..	102	APRODINE TABLET.....	16
ADVANCED TRAVEL 30G LANCETS.....	102	Ascomp with Codeine.....	114
ADVOCATE 26G LANCETS 26 G,STERILE.....	102	ASSURE COMFORT 30G LANCETS	102
ADVOCATE 26G LANCETS STERILE.....	102	ASSURE HAEMOLANCE PLUS 18G	102
ADVOCATE 30G LANCETS TWIST TOP.....	102	ASSURE HAEMOLANCE PLUS 21G	102
Afinitor Disperz.....	89	ASSURE HAEMOLANCE PLUS 25G	102
Afinitor oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg.....	89	ASSURE HAEMOLANCE PLUS 28G	102
ALA-HIST IR 2 MG TABLET.....	16	ASSURE LANCE 25G LANCETS.....	102
ALA-HIST PE TABLET	16	ASSURE LANCE 28G LANCETS.....	102
ALAVERT 10 MG ODT.....	16	ASSURE LANCE PLUS 21G LANCETS.....	102
Alecensa.....	10	ASSURE LANCE PLUS 25G LANCETS.....	102
		ASSURE LANCE PLUS 30G LANCETS.....	102
		Aubagio.....	237
		Austedo oral tablet 12 mg, 6 mg, 9 mg.....	63
		Avastin.....	34
		Avonex (with albumin).....	135
		Avonex intramuscular pen injector kit...	135

Avonex intramuscular syringe kit.....	135	CARESENS ULTRA THIN 30G	
BANOPHEN 25 MG CAPSULE.....	19	LANCET.....	102
BANOPHEN 25 MG TABLET.....	19	CARETOUCH TWIST 28G LANCET	102
BANOPHEN 50 MG CAPSULE.....	19	CARETOUCH TWIST 30G LANCET	102
BANOPHEN ALLERGY 12.5 MG/5		carisoprodol.....	122
ML A/F.....	19	Cerdelga.....	74
Bavencio.....	28	CETIRIZINE HCL 1 MG/ML SOLN	
BD LANCETS 33G.....	102	CHILDREN, S/F, GRAPE (OTC).....	16
BD MICROTAINER 21G LANCETS.	102	CETIRIZINE HCL 10 MG CHEW	
BD MICROTAINER 30G LANCETS.	102	TAB CHILDREN'S, OUTER, U-D.....	16
BD ULTRA-FINE 33G LANCETS.....	102	CETIRIZINE HCL 10 MG TABLET.....	16
BD ULTRA-FINE II 30G LANCETS..	102	CETIRIZINE HCL 5 MG CHEW TAB	
Beleodaq.....	32	CHILDREN'S, OUTER, U-D.....	16
BENADRYL ALLERGY 25 MG		CETIRIZINE HCL 5 MG TABLET.....	16
ULTRATB ULTRATAB.....	19	CHILD ACETAMINOPHEN 80	
Bendeka.....	33	MG/2.5 ML ORAL SYRINGE 50'S, U-	
Benlysta intravenous.....	31	D, ORAL SYR.....	6
Benlysta subcutaneous.....	31	CHILD ALLEGRA ALLERGY 30	
benztropine oral.....	111	MG/5 ML SUSPENSION.....	16
Besponsa.....	133	CHILD DOMETUSS-DA LIQUID.....	16
Betaseron subcutaneous kit.....	136	CHILD LORATADINE 5 MG/5 ML	
bexarotene.....	35	SYR GRAPE, S/F.....	16
Blinicyto intravenous kit.....	36	CHILD NON-ASPIRIN 160 MG/5 ML	
BLOOD LANCETS 30G EASY TWIST		CHILDREN'S.....	6
.....	102	CHILD PAIN-FEVER 160 MG/5 ML.....	6
Bosulif oral tablet 100 mg, 500 mg.....	38	CHILD PAIN-FEVER 160 MG/5 ML	
BROTAPP LIQUID.....	16	A/F, ASA/F, IBU/F.....	6
BULLSEYE MINI SAFETY 21G.....	102	CHILD TRIAMINIC COLD &	
BULLSEYE MINI SAFETY 25G		ALLERGY.....	16
LANCT.....	102	CHILD WAL-TAP COLD-ALLERGY	
buprenorphine HCl sublingual.....	177	ELX.....	16
Butalbital Compound W/Codeine.....	114	CHILD WAL-ZYR 1 MG/ML	
butalbital-acetaminop-caf-cod.....	114	SOLUTION CHERRY.....	16
butalbital-acetaminophen oral tablet 50-		CHILDREN'S COLD & ALLERGY	
325 mg.....	114	ELXR A/F.....	16
butalbital-acetaminophen-caff oral		CHILDREN'S SILFEDRINE LIQ.....	16
capsule 50-325-40 mg.....	114	CHILDREN'S WAL-FEX 30 MG/5	
butalbital-acetaminophen-caff oral		ML.....	16
tablet 50-325-40 mg.....	114	CHILD'S ALLER-TEC 1 MG/ML	
butalbital-aspirin-caffeine.....	114	SOLN.....	16
Cabometyx oral tablet 20 mg, 40 mg, 60		CHILD'S BENADRYL 12.5 MG/5 ML.	19
mg.....	44	CHILDS SUDAFED 15 MG/5 ML LIQ	
Capacet.....	114	NON-DROWSY, A/F, S/F.....	16
Caprelsa oral tablet 100 mg, 300 mg.....	258	CHILD'S WAL-ZYR 10 MG CHEW	
CAREONE ULTRA THIN LANCET.	102	TAB.....	16

CHLORHIST 4 MG TABLET.....	16	CVS PRENATAL VITAMIN TABLET	195
CHLORPHENIRAMINE ER 12 MG		195
TAB.....	16	CVS THIN 26G LANCETS.....	102
chlorzoxazone oral tablet 500 mg.....	122	CVS ULTRA THIN 30G LANCETS...	102
Cimzia.....	49	CVS WOMEN'S PRENATAL + DHA.	195
Cimzia Powder for Reconst.....	49	cyclobenzaprine oral tablet 10 mg, 5 mg	122
Cinqair.....	202	Cyramza.....	200
Cinryze.....	42	DAILY PRENATAL COMBO PACK.	195
CLEVER CHEK ULTRA THIN 30G..	102	DAILYHIST-1 1.34 MG TABLET.....	16
COAGUCHEK LANCETS.....	102	Daklinza.....	55
Cold-Allergy-Sinus.....	16	DALLERGY 1-5 MG TABLET.....	16
CombiPatch.....	119	Daraprim.....	197
Cometriq.....	43	Darzalex.....	59
COMFORT EZ SAFETY 21G		DAYHIST ALLERGY 1.34 MG	
LANCETS.....	102	TABLET 12 HR RELIEF.....	16
COMFORT EZ SAFETY 23G		DAYHIST TABLET.....	16
LANCETS.....	102	Digitek.....	118
COMFORT EZ SAFETY 28G		Digox.....	118
LANCETS.....	102	DIGOXIN 0.25 MG/ML SYRINGE...	118
COMFORT LANCETS.....	102	digoxin injection solution.....	118
COMPOZ 25 MG GELCAP.....	19	digoxin oral solution 50 mcg/mL.....	118
CONEX SOLUTION.....	16	digoxin oral tablet.....	118
CONEX TABLET.....	16	DIMAPHEN ELIXIR A/F, GRAPE,	
Copaxone subcutaneous syringe.....	99	GLUTEN-F.....	16
Cosentyx.....	216	DIMETAPP COLD & CONGEST	
COSENTYX (150 MG/ML) 300 MG		LIQUID.....	16
DOSE-2 PENS.....	216	DIPHEDRYL 12.5 MG/5 ML ELIXIR..	19
COSENTYX (150 MG/ML) 300 MG		DIPHENHIST 12.5 MG/5 ML SOLN...	19
DOSE-2 SYRINGES.....	216	DIPHENHIST 25 MG CAPSULE.....	19
Cosentyx Pen.....	216	DIPHENHIST 25 MG CAPTAB	
Cotellic.....	51	CAPTAB.....	19
CVS ALLERGY-D TABLET.....	16	DIPHENHYDRAMINE 25 MG	
CVS CHILD ALLERGY 10 MG CHW		CAPSULE (OTC).....	19
TB 24 HR,INDOOR/OUTDOOR.....	16	DRAMAMINE LESS DROWSY 25	
CVS CHILD PAIN RLF 160 MG/5 ML		MG TB.....	16
CHILDREN'S, A/F.....	6	dronabinol.....	46
CVS COLD & COUGH NIGHTTIME		DROPLET 30G LANCETS.....	102
LIQ.....	16	Duavee.....	119
CVS MICRO THIN 33G LANCETS		Dupixent.....	69
UNIVERSAL 1.....	102	EASY COMFORT 30G LANCETS	
CVS MOTION SICKNESS RELIEF		30G,TWIST TOP,STRL.....	102
TAB CHEWABLE TABLET.....	16	EASY TOUCH 28G LANCETS	
CVS NOSE DROPS.....	16	28G,PULL TOP,STERILE.....	102
CVS PRENATAL GUMMY		EASY TOUCH SAFETY 21G	
VITAMINS.....	195	LANCETS.....	102

EASY TOUCH SAFETY 23G LANCETS.....	102	estradiol transdermal patch semiweekly. 119	
EASY TOUCH SAFETY 26G LANCETS.....	102	estradiol transdermal patch weekly.....	119
EASY TOUCH TWIST 28G LANCETS.....	102	estradiol-norethindrone acet.....	119
EASY TOUCH TWIST 30G LANCETS.....	102	estropipate.....	119
EASY TOUCH TWIST 32G LANCETS.....	102	eszopiclone.....	121
EASY TOUCH TWIST 33G LANCETS.....	102	Exondys 51.....	88
EASY TWIST & CAP 28G LANCETS.....	102	EXPECTA PRENATAL COMBO PACK.....	195
ED CHLORPED DROPS.....	16	Extavia subcutaneous kit.....	136
ED CHLORPED JR SYRUP.....	16	E-Z JECT LANCETS.....	102
ED-A-HIST 4 MG-10 MG TABLET.....	16	EZ SMART 28G LANCETS.....	102
EMBRACE 30G LANCETS.....	102	E-ZJECT COLOR 32G LANCETS.....	102
Emflaza oral suspension.....	61	E-ZJECT COLOR 33G LANCETS.....	102
Emflaza oral tablet 18 mg, 30 mg, 36 mg, 6 mg.....	61	E-ZJECT SUPER THIN 30G LANCETS SUPER THIN.....	102
Empliciti.....	76	Farydak.....	182
Enbrel subcutaneous recon soln.....	86	fentanyl citrate.....	94
Enbrel subcutaneous syringe.....	86	FEXOFENADINE HCL 180 MG TABLET 24 HOUR, NON-DROWSY (OTC).....	16
Enbrel SureClick.....	86	FEXOFENADINE HCL 30 MG/5 ML..	16
ENTRE-HIST PSE LIQUID.....	16	FEXOFENADINE HCL 60 MG TABLET INDOOR/OUTDOOR (OTC)	16
Epclusa.....	222	FIFTY50 SAFETY SEAL 30G LANCET.....	102
EPOGEN 10,000 UNITS/ML VIAL SDV, P/F, OUTER.....	82	FIFTY50 SAFETY SEAL 32G LANCET.....	102
Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL.....	82	FINE 30 UNIVERSAL 30G LANCETS	102
EQ ALLERGY & SINUS RELIEF TAB.....	16	FINGERSTIX LANCETS.....	102
EQ ALLERGY RELIEF 25 MG TABLET.....	19	Flector.....	65
EQL ALLERGY RELIEF 10 MG ODT NON-DROWSY.....	16	FOLIC ACID 400 MCG TABLET S/F,P/F,LACTOSE-FREE.....	96
EQL NASAL DECNGSTNT NOSE DROPS.....	16	FORA 30G LANCETS TWIST OFF,SINGLE USE.....	102
EQL PRENATAL VITAMIN TABLET	195	FORACARE 30G LANCETS.....	102
Erivedge.....	261	Forteo.....	238
Esbriet oral capsule.....	191	FREESTYLE 28G LANCETS.....	102
Esbriet oral tablet 267 mg, 801 mg.....	191	FREESTYLE UNISTIK 2 LANCETS.....	102
estradiol oral.....	119	GATTEX 5 MG 30-VIAL KIT.....	234
		Gattex One-Vial.....	234
		Gazyva.....	167
		Genotropin.....	227
		Genotropin MiniQuick.....	227
		GERI-DRYL 12.5 MG/5 ML LIQUID..	19

Gilenya.....	95	INCONTROL SUPER THIN 30G	
Gilotrif.....	9	LANCT.....	102
GLUCOCOM 28G LANCETS.....	102	INCONTROL ULTRA THIN 28G	
GLUCOCOM 30G LANCETS.....	102	LANCT.....	102
GLUCOCOM 33G LANCETS.....	102	INFANT PAIN RELV 80 MG/0.8 ML	
glyburide.....	120	A/F, GLUTEN-FREE.....	6
glyburide micronized.....	120	INFANT'S PAIN RELIEF SUSP	
glyburide-metformin.....	120	DROP.....	6
GMATE 30G LANCETS.....	102	Inflectra.....	131
GNP UNIVERSAL 1 STANDARD		Ingrezza oral capsule 40 mg, 80 mg.....	257
21G.....	102	INJECT EASE 28G LANCETS.....	102
GNP UNIVERSAL 1 SUPER THIN		INJECT EASE 30G LANCETS.....	102
30G.....	102	Inlyta oral tablet 1 mg, 5 mg.....	29
Gocovri oral capsule,extended release		Intron A injection.....	134
24hr 137 mg, 68.5 mg.....	14	INVACARE 30G LANCETS.....	102
GS PRENATAL VITAMINS TABLET		Iprivask.....	62
.....	195	Iressa.....	97
guanfacine oral tablet.....	115	Jakafi.....	211
Haegarda.....	42	Juxtapid oral capsule 10 mg, 20 mg, 30	
Harvoni.....	142	mg, 40 mg, 5 mg, 60 mg.....	147
HEALTHY ACCENTS UNILET 30G.....	102	Kalydeco.....	138, 139
Herceptin.....	248	Kanuma.....	214
Hetlioz.....	233	Keveyis.....	64
HISTEX-PE SYRUP.....	16	Kevzara.....	213
HIST-PSE SOLUTION.....	16	Keytruda.....	189
HM Z-SLEEP 25 MG SOFTGEL.....	19	Kineret.....	15
Humatrope.....	224	KINNEY BRAND 23G LANCETS.....	102
Humira.....	7	Kisqali.....	203
Humira Pediatric Crohn's Start.....	7	Kisqali Femara Co-Pack oral tablet 200	
Humira Pen.....	7	mg/day(200 mg x 1)-2.5 mg, 400	
Humira Pen Crohn's-UC-HS Start.....	7	mg/day(200 mg x 2)-2.5 mg, 600	
Humira Pen Psoriasis-Uveitis.....	7	mg/day(200 mg x 3)-2.5 mg.....	203
hydroxyprogesterone caproate.....	123	Korlym.....	155
Ibrance.....	180	KPN TABLET.....	195
Iclusig oral tablet 15 mg, 45 mg.....	193	KRO CHILD NITE TIME COLD &	
Idhifa.....	78	CGH.....	16
Ilaris (PF).....	45	KRO UNIVERSAL 1 THIN 26G	
imatinib oral tablet 100 mg, 400 mg.....	126	LANCT.....	102
Imbruvica.....	124	KROGER SUPER THIN LANCETS..	102
Imfinzi.....	70	Kynamro.....	156
imiquimod.....	127	Kyprolis intravenous recon soln 30 mg,	
Imlygic injection suspension 10exp6 (1		60 mg.....	47
million) PFU/mL, 10exp8 (100 million)		LANCETS THIN 23G.....	102
PFU/mL.....	232	LANCETS ULTRA THIN 26G.....	102
		Lanoxin oral tablet 187.5 mcg, 62.5 mcg	118

Lartruvo.....	170	Mircera.....	85
Lazanda.....	93	MONOLET 21G LANCETS.....	102
Lemtrada.....	11	MONOLET THIN 28G LANCETS.....	102
Lenvima.....	144	MYGLUCOHEALTH 30G LANCETS.....	102
Letairis.....	79	Mylotarg.....	98
lidocaine topical adhesive		NASAL DECONGEST-ANTI HIST	
patch, medicated.....	145	TAB.....	16
lidocaine topical ointment.....	146	NASAL-SINUS DECONGEST TAB.....	16
LITE TOUCH 30G LANCETS.....	102	Natpara.....	183
LITE TOUCH 33G LANCETS.....	102	Nerlynx.....	161
LITTLE REMEDIES FEVER 160		Nexavar.....	230
MG/5 A/F,D/F, GLUTEN-FREE.....	6	Ninlaro.....	140
LOHIST-D LIQUID.....	16	nitrofurantoin macrocrystal.....	113
LOMAIRA 8 MG TABLET.....	21	nitrofurantoin monohyd/m-cryst.....	113
LONGS THIN LANCETS 30G 30G....	102	NOHIST-LQ LIQUID.....	16
Lonsurf oral tablet 15-6.14 mg, 20-8.19		NON-ASPIRIN CHILD'S DROPS.....	6
mg.....	254	Norditropin FlexPro.....	227
LORATADINE 10 MG TABLET.....	16	NORTEMP 80 MG/0.8 ML DROP.....	6
Lynparza oral capsule.....	169	Northera.....	68
Lynparza oral tablet.....	169	NOSE DROPS.....	16
MAPAP 160 MG/5 ML LIQUID.....	6	NOVA SAFETY 23G LANCETS.....	102
MAPAP 160 MG/5 ML SUSPENSION....	6	NOVA SAFETY 28G LANCETS.....	102
Margesic.....	114	NOVA SUREFLEX THIN LANCETS.....	102
Mavyret.....	100	Nucala.....	151
MECLIZINE 12.5 MG CAPLET		Nuplazid.....	190
CAPLET (OTC).....	16	Nutropin AQ.....	228
MECLIZINE 25 MG TABLET (OTC)...	16	Nutropin AQ Nuspin.....	228
MEDI-MECLIZINE 25 MG TABLET		NYTOL 25 MG QUICKCAPS	
OUTER, F/C.....	16	CAPLET CAPLET.....	19
MEDI-PHEDRINE 30 MG TABLET....	16	Ocaliva.....	166
MEDISENSE THIN 28G LANCETS... ..	102	Ocrevus.....	168
MEDLANCE PLUS 21G LANCETS		Odomzo.....	229
UNIVERSAL, 1.8MM.....	102	Ofev.....	163
MEDLANCE PLUS 30G LANCETS		Olysio.....	219
SUPERLITE, 1.2MM.....	102	Omnitrope.....	224
MEDLANCE PLUS LITE 25G		ON CALL 30G LANCET.....	102
LANCETS STERILE, 1.5MM.....	102	ON CALL PLUS 30G LANCET.....	102
Mekinist oral tablet 0.5 mg, 2 mg.....	247	Oncaspar.....	26
Menest.....	119	ONE A DAY PRENATAL DHA	
Metaxall.....	122	PACK 30 LIQ GELS, 30 TABS.....	195
metaxalone.....	122	ONE TOUCH DELICA 33G	
methocarbamol oral.....	122	LANCETS.....	102
MICROLET LANCETS.....	102	ONE-A-DAY PRENATAL 1 DHA	
Mimvey.....	119	SFGL.....	195
Mimvey Lo.....	119		

ONETOUCH DELICA 30G LANCETS.....	102	PRENATAL + DHA COMBO PACK .	195
ONETOUCH DELICA 33G LANCETS.....	102	PRENATAL 19 CHEWABLE TABLET (OTC).....	195
ONETOUCH SURESOFT LANCING DEV	102	PRENATAL DHA+COMPLETE PRENATAL.....	195
ONETOUCH ULTRASOFT LANCETS.....	102	PRENATAL FORMULA TABLET ...	195
Onfi oral suspension.....	50	PRENATAL GUMMIES.....	195
Onfi oral tablet 10 mg, 20 mg.....	50	PRENATAL MULTI + DHA SOFTGEL P/F, GLUTEN-FREE.....	195
Opdivo.....	165	PRENATAL MULTI-DHA SOFTGEL	195
Opsumit.....	79	PRENATAL MULTIVITAMIN TABLET	195
Orencia.....	3	PRENATAL MULTIVITAMIN-DHA SFGL.....	195
Orencia (with maltose).....	2	PRENATAL ONE TABLET	195
Orencia ClickJect.....	3	PRENATAL TABLET	195
Orenitram.....	249	PRENATAL TABLET (OTC).....	195
Orkambi.....	150	PRENATAL TABLET OUTER (OTC)	195
Otezla.....	22	PRENATAL VITAMIN TABLET	195
Otezla Starter.....	22	PRENATAL VITAMINS TABLET PHOSPHORUS FREE.....	195
PEDIACARE FEVER REDUCER SUSP.....	6	PRENATAL-1 CAPSULE.....	195
PEDIAVENT 1 MG TABLET CHEW... 16		PRESSURE ACTIVATED 21G LANCETS.....	102
PEDIAVENT 2 MG/5 ML SYRUP	16	PRESSURE ACTIVATED 28G LANCETS.....	102
PERRY PRENATAL CAPSULE.....	195	PRO COMFORT 30G LANCETS.....	102
PHARMACIST CHOICE 30G LANCETS ULTRA THIN.....	102	PRO COMFORT 31G LANCET	102
Phenadoz.....	112	Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL.....	82
PHENTERMINE 15 MG CAPSULE.....	21	PRODIGY PRESSURE ACTIVATED 28G.....	102
PHENTERMINE 30 MG CAPSULE.....	21	PRODIGY SAFETY 26G LANCETS..	102
PHENTERMINE 37.5 MG CAPSULE..	21	PRODIGY TWIST TOP 28G LANCET	102
PHENTERMINE 37.5 MG TABLET ...	21	PROFE FORTE CAPSULE.....	195
PHENYLEPHRINE-PYRILAMINE 10-25	16	Promacta.....	77
PHENYLHISTINE DH LIQUID (OTC).....	16	promethazine oral.....	112
Plegridy.....	135	promethazine rectal.....	112
POLY-VITA WITH IRON DROPS.....	187	PROMETHAZINE VC-CODEINE SYRUP.....	16
POLYVITAMIN W-IRON DROPS.....	187		
Pomalyst.....	192		
Portrazza.....	160		
Praluent Pen.....	12		
Praluent Syringe.....	12		
Premarin oral.....	119		
Premphase.....	119		
Prempro.....	119		

PROMETHAZINE-CODEINE SYRUP.....	16	RA NON-ASPIRIN 160 MG/5 ML CHILDREN'S,CHERRY.....	6
PROMETHAZINE-DM SYRUP.....	16	RA ONE DAILY PRENATAL DHA PACK 30'S TAB & 30'S CAP.....	195
Promethegan.....	112	RA PRENATAL TABLET.....	195
PSEUDOEPHED 30 MG/5 ML SOLN..	16	RA SLEEP TABLET.....	19
PSEUDOEPHEDRINE 30 MG TABLET.....	16	RA SLEEP-AID SOFTGEL.....	19
PSEUDOEPHEDRINE 60 MG TABLET EX-STR, NON DROWSY (OTC).....	16	Radicava.....	71
PUSH BUTTON SAFETY 21G LANCET.....	102	Ravicti.....	107
PUSH BUTTON SAFETY 28G LANCET.....	102	READYLANCE 21G SAFETY LANCETS.....	102
PV CHILDREN'S NON-ASA LIQ.....	6	READYLANCE 23G SAFETY LANCETS.....	102
PV INFANT NON-ASA 80 MG/0.8 ML ASPIRIN FREE, A/F.....	6	READYLANCE 26G SAFETY LANCETS.....	102
PV NYT-TIME SLEEP 25 MG CAPLET.....	19	READYLANCE 28G SAFETY LANCETS.....	102
PV PRENATAL FORMULA TABLET.....	195	READYLANCE 30G SAFETY LANCETS.....	102
PV SINUS NIGHTTIME TABLET.....	16	Rebif (with albumin).....	135
PYRILAMINE-PHENYLEPHRINE SUSP.....	16	Rebif Rebidose.....	135
QC UNILET SUPER THIN 30G LANCT.....	102	Rebif Titration Pack.....	135
quinine sulfate.....	199	RELIAMED 30G LANCETS.....	102
RA ACTA-TABS PE TABLET.....	16	RELIAMED SAFETY 23G LANCETS.....	102
RA ALLERGY MED 25 MG CAPSULE.....	19	RELIAMED SAFETY 28G LANCETS LATEX-FREE.....	102
RA ALLERGY MED 25 MG TABLET.....	19	RELIAMED SAFETY SEAL 28G LANCT.....	102
RA ALLERGY MED 25 MG TABLET COATED MINITABS.....	19	RELIAMED SAFETY SEAL 30G LANCT.....	102
RA ALLERGY PLUS SINUS TABLET.....	16	RELION THIN 26G LANCETS.....	102
RA CHILD CETIRIZINE 10 MG CHEW 24 HR,INDOOR/OUTDOOR... ..	16	RELION ULTRA THIN PLUS 33G....	102
RA E-ZJECT 26G LANCETS.....	102	RELION ULTRA THIN PLUS LANCETS.....	102
RA E-ZJECT 28G LANCETS.....	102	Relistor oral.....	153
RA INFANT FEVER-PAIN REL SUSP.....	6	Relistor subcutaneous solution.....	152
RA LORATADINE 10 MG TABLET NON-DROWSY.....	16	Relistor subcutaneous syringe.....	152
RA MOTION SICKNESS RLF TB CHEW RASPBERRY FLAVOR.....	16	Remicade.....	128
		Remodulin.....	252
		Renflexis.....	130
		Repatha Pushtonex.....	90
		Repatha SureClick.....	90
		Repatha Syringe.....	90
		Revlimid.....	143

RIGHT STEP PRENATAL VIT TAB..	195	SM PRENATAL VITAMINS TABLET	195
RIGHTEST GL300 30G LANCETS.....	102	SM SINUS AND ALLERGY TABLET	
RITIFED SYRUP.....	16	MAXIMUM STRENGTH.....	16
Rituxan.....	208	SM THIN LANCETS 26G.....	102
Rituxan Hycela.....	209	SMART SENSE COLOR 33G	
Rubraca.....	210	LANCETS.....	102
Rydapt.....	154	SMART SENSE STANDARD 21G.....	102
RYMED TABLET.....	16	SMART SENSE THIN 26G LANCETS	
SAFETY 21G LANCETS LATEX-		102
FREE.....	102	SMARTEST LANCET.....	102
SAFETY 28G LANCETS LATEX-		SOFT TOUCH LANCETS.....	102
FREE.....	102	SOLUS V2 28G LANCETS.....	102
SAFETY LANCETS 26G.....	102	SOLUS V2 30G TWIST LANCETS.....	102
SAFETY SEAL 28G LANCETS.....	102	Sovaldi.....	221
SAFETY SEAL 30G LANCETS.....	102	Sprycel oral tablet 100 mg, 140 mg, 20	
SAFETY-LET 30G LANCETS.....	102	mg, 50 mg, 70 mg, 80 mg.....	60
Saizen.....	224	Stelara intravenous.....	256
Saizen click.easy.....	224	Stelara subcutaneous syringe.....	255
SB LANCETS THIN 28G.....	102	STERILANCE TL TWIST 30G	
Serostim subcutaneous recon soln 4 mg,		LANCET.....	102
5 mg, 6 mg.....	225	STERILANCE TL TWIST 32G	
SHOPKO ON-THE-GO 30G		LANCET.....	102
LANCETS GENTLE.....	102	Stivarga.....	201
SILADRYL 12.5 MG/5 ML LIQUID.....	19	Strensiq.....	23
SILAPAP INFANT'S DROPS		STUART ONE CAPSULE.....	195
INFANT'S.....	6	SUDOGEST 30 MG TABLET BOXED.....	16
sildenafil (antihypertensive) intravenous	186	SUDOGEST 60 MG TABLET.....	16
sildenafil (antihypertensive) oral.....	185	SUDOGEST SINUS & ALLERGY	
Siliq.....	41	TAB.....	16
SIMILAC PRENATAL COMBO		SUPER THIN 28G LANCETS	
PACK.....	195	STERILE.....	102
SIMPLY SLEEP 25 MG CAPLET		SUPER THIN 33G LANCETS.....	102
CAPLET.....	19	SUPHEDRIN LIQUID.....	16
Simponi.....	109	SURE COMFORT 18G LANCETS.....	102
Simponi ARIA.....	108	SURE COMFORT 21G LANCETS.....	102
SINGLE-LET LANCETS.....	102	SURE COMFORT 23G LANCETS.....	102
Sirturo.....	30	SURE COMFORT 28G LANCETS.....	102
SM ADULT NASAL		SURE COMFORT 30G LANCETS.....	102
DECONGESTANT LQ.....	16	SURE-LANCE 26G LANCETS.....	102
SM ALLERGY RELIEF 1.34 MG TAB	16	SURE-LANCE FLAT LANCETS.....	102
SM COLD & ALLERGY TABLET.....	16	SURE-LANCE THIN 28G LANCETS	102
SM COLOR LANCETS 21G.....	102	SURE-LANCE ULTRA THIN 30G.....	102
SM LANCETS 21G.....	102	SURE-TOUCH LANCET.....	102
SM ONE DAILY PRENATAL		Sutent.....	231
COMBO PK.....	195		

Sylatron.....	188	TOPCARE UNIVERSAL1 33G	
Sylvant.....	218	LANCETS.....	102
SymlinPen 120.....	194	TOPCARE UNIVERSAL1 THIN	
SymlinPen 60.....	194	LANCET ULTRA THIN, 30G.....	102
Synagis.....	181	Tracleer.....	79
Synribo.....	171	TRAVEL SICKNESS 25 MG TAB	
Tafinlar.....	54	CHEW.....	16
Tagrisso.....	178	TRAVEL-EASE 25 MG TABLET.....	16
TALTZ 80 MG/ML AUTOINJECTOR		Tremfya.....	110
P/F,L/F,SDV,OUTER.....	141	tretinoin.....	245
Taltz Autoinjector (3 Pack).....	141	TRETINOIN GEL MICRO 0.04%	
Taltz Syringe.....	141	TUBE.....	245
Tarceva oral tablet 100 mg, 150 mg, 25		TRETINOIN GEL MICRO 0.1%	
mg.....	81	TUBE.....	245
Targretin oral.....	35	tretinoin microspheres topical gel with	
Targretin topical.....	35	pump.....	245
Tasigna.....	162	trihexyphenidyl.....	111
Tecentriq.....	27	TRIP-PSE LIQUID.....	16
Tecfidera oral capsule,delayed		TRI-VI-SOL DROPS.....	187
release(DR/EC) 120 mg, 120 mg (14)-		TRI-VITA DROPS.....	187
240 mg (46), 240 mg.....	66	TRI-VITAMIN DROPS.....	187
TECHLITE 28G LANCETS.....	102	TRUEPLUS 26G LANCETS.....	102
TECHLITE 30G LANCETS.....	102	TRUEPLUS 33G LANCETS.....	102
Technivie.....	173	TRUEPLUS SAFETY 28G LANCETS	
TELCARE ULTRA THIN 30G		28G, STERILE.....	102
LANCETS.....	102	TRUEPLUS SUPER THIN 28G	
Temodar intravenous.....	236	LANCET 28G, STERILE.....	102
Tencon oral tablet 50-325 mg.....	114	TRUEPLUS ULTRA THIN 30G	
testosterone cypionate.....	239	LANCET.....	102
testosterone enanthate.....	239	Tymlos.....	1
testosterone transdermal gel.....	239	Tysabri.....	159
testosterone transdermal gel in metered-		Tyvaso.....	251
dose pump 12.5 mg/ 1.25 gram (1 %).	239	ULTILET 28G LANCETS.....	102
testosterone transdermal gel in packet...	239	ULTILET 30G LANCETS.....	102
tetrabenazine.....	240	ULTILET 33G LANCETS.....	102
Thalomid.....	241	ULTILET BASIC 30G LANCETS.....	102
THERANATAL CORE NUTRITION		ULTILET CLASSIC 26G LANCETS..	102
TAB.....	195	ULTILET CLASSIC 28G LANCETS..	102
THERANATAL OVAVITE COMBO		ULTILET CLASSIC 30G LANCETS..	102
PACK.....	195	ULTILET CLASSIC 33G LANCETS..	102
THERANATAL PLUS COMBO		ULTILET SAFETY 23G LANCETS...	102
PACK.....	195	ULTRA THIN 28G LANCETS	
THIN LANCETS 28G.....	102	ULTRA THIN.....	102
thioridazine.....	117	ULTRA THIN 30G LANCETS	
		STERILE.....	102

ULTRA THIN 31G LANCETS.....	102	Uptravi oral tablets,dose pack.....	217
ULTRA THIN 33G LANCETS.....	102	VALU-DRYL ALLERGY MED TAB...19	
ULTRALANCE 26G LANCETS.....	102	VALU-TAPP DECONGESTANT	
ULTRALANCE 28G LANCETS.....	102	DROP.....	16
ULTRA-THIN II 26G LANCET.....	102	VAZOBID-PD SUSPENSION.....	16
ULTRA-THIN II 28G LANCETS.....	102	VAZOTAB 10-25 MG TABLET.....	16
ULTRA-THIN II 30G LANCETS.....	102	Velcade.....	37
ULTRATLC LANCETS.....	102	Venclexta oral tablet 10 mg, 100 mg, 50	
UNILET COMFORTOUCH 26G		mg.....	260
LANCETS.....	102	Venclexta Starting Pack.....	260
UNILET COMFORTOUCH LANCET		Verzenio.....	4
.....	102	VICKS QLEARQUIL NIGHT 25 MG...19	
UNILET EXCELITE II LANCET.....	102	Viekira Pak.....	175
UNILET EXCELITE LANCET.....	102	Viekira XR.....	175
UNILET GP LANCET.....	102	Vimizim.....	75
UNILET LANCET SUPERLITE.....	102	VINACAL B PRENATAL COMBO	
UNILET MICRO THIN 33G		PACK.....	195
LANCETS.....	102	Vosevi.....	223
UNILET ULTRA THIN 28G		Votrient.....	184
LANCETS.....	102	V-R TRIACTING ORANGE SYRUP... 16	
UNISOM 50 MG SLEEPGELS		WAL-ACT D COLD & ALLERGY	
SOFTGEL.....	19	TAB.....	16
UNISTIK 3 COMFORT LANCET.....	102	WAL-DRYL ALLERGY 12.5 MG/5	
UNISTIK 3 EXTRA 21G LANCETS...102		ML CHILDREN,A/F,S/F,D/F.....	19
UNISTIK 3 GENTLE ON-THE-GO		WAL-DRYL ALLERGY 25 MG	
30G.....	102	CAPSULE.....	19
UNISTIK 3 NORMAL 23G LANCETS		WAL-DRYL ALLERGY 25 MG	
.....	102	MINITAB MINITAB, COATED.....	19
UNISTIK 3 SAFETY 21G LANCETS.102		WAL-DRYL-D ALLERGY & SINUS	
UNISTIK CZT COMFORT 28G		CPT.....	16
LANCET.....	102	WAL-FEX ALLERGY 180 MG	
UNISTIK CZT NORMAL 23G		TABLET.....	16
LANCETS.....	102	WAL-FEX ALLERGY 60 MG	
UNISTIK SAFETY 28G LANCET.....	102	TABLET.....	16
UNISTIK SAFETY 30G LANCETS...102		WAL-FINATE 4 MG TABLET.....	16
UNISTIK TOUCH 21G LANCETS.....	102	WAL-FINATE-D TABLET.....	16
UNISTIK TOUCH 23G LANCETS.....	102	WALGREENS ULTRA THIN	
UNISTIK TOUCH 28G LANCETS.....	102	LANCETS.....	102
UNISTIK TOUCH 30G LANCETS.....	102	WAL-ITIN 10 MG ODT NON-	
Unituxin.....	67	DROWSY.....	16
UNIVERSAL 1 33G LANCETS FOR		WAL-ITIN 10 MG TABLET NON-	
MEIJER.....	102	DROWSY,24 HR RLF.....	16
Uptravi oral tablet 1,000 mcg, 1,200		WAL-ITIN 5 MG/5 ML SYRUP	
mcg, 1,400 mcg, 1,600 mcg, 200 mcg, 400		CHILDREN'S, GRAPE.....	16
mcg, 600 mcg, 800 mcg.....	217		

WAL-PHED 30 MG TABLET NON-DROWSY	16
WAL-PHED PE SINUS-ALLERGY TAB.....	16
WAL-PHED SINUS AND ALLERGY TAB.....	16
WAL-SLEEP Z 25 MG ODT	19
WAL-SLEEP Z 25 MG SOFTGEL.....	19
WAL-SOM 25 MG ODT.....	19
WAL-SOM 50 MG SOFTGEL SOFTGEL	19
WAL-TAP ELIXIR.....	16
WAL-ZYR 10 MG TABLET	16
Xadago.....	212
Xalkori.....	53
Xeljanz.....	244
Xeljanz XR.....	244
Xermelo.....	235
Xifaxan oral tablet 200 mg.....	204
Xifaxan oral tablet 550 mg.....	205
Xolair.....	172
Xtandi.....	80
Yervoy.....	137
Yondelis.....	246
zaleplon.....	121
Zebutal oral capsule 50-325-40 mg.....	114
Zejula.....	164
Zelboraf.....	259
Zepatier.....	72
ZEPHREX-D 30 MG TABLET	16
Zinbryta.....	57
zolpidem oral.....	121
Zomacton.....	224
Zorbtive.....	226
Zydelig.....	125
Zykadia.....	48
Zytiga.....	5